



**HAL**  
open science

## Functional and cellular localization diversity associated with Fukutin-related protein patient genetic variants

Sara F Henriques, Evelyne Gicquel, Justine Marsolier, Isabelle Richard

### ► To cite this version:

Sara F Henriques, Evelyne Gicquel, Justine Marsolier, Isabelle Richard. Functional and cellular localization diversity associated with Fukutin-related protein patient genetic variants. *Human Mutation*, 2019, 40 (10), pp.1874-1885. 10.1002/humu.23827 . hal-02177499

**HAL Id: hal-02177499**

**<https://univ-evry.hal.science/hal-02177499>**

Submitted on 2 Mar 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Functional and cellular localization diversity associated with  
Fukutin related protein patient genetic variants**

Journal:	<i>Human Mutation</i>
Manuscript ID	humu-2018-0564.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Henriques, Sara; Genethon, INSERM UMR951 Gicquel, Evelyne; Genethon, INSERM UMR951 Marsolier, Justine; Genethon, INSERM UMR951 Richard, Isabelle; Genethon, INSERM UMR951 Evry, Île-de-France, FR
Key Words:	FKRP, LGMD2I, dystroglycan, missense mutations, protein quality control, glycosylation

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 Functional and cellular localization diversity associated with  
5  
6  
7  
8 Fukutin related protein patient genetic variants  
9  
10

11 Sara F. Henriques<sup>1</sup>, Evelyne Gicquel<sup>1</sup>, Justine Marsolier<sup>1</sup> and Isabelle Richard<sup>1</sup>

12  
13  
14  
15 1 INTEGRARE Research Unit, UMR951, Généthon, INSERM, Université Evry Val  
16  
17 d'Essonne, Université Paris-Saclay, 91002, Evry, France  
18  
19

20  
21  
22  
23  
24 **Funding information**  
25

26  
27 Généthon is part of the Biotherapies Institute for Rare Diseases (BIRD) which is supported by  
28  
29 the Association Française contre les Myopathies (AFM-Téléthon). SH was supported by a  
30  
31 PhD fellowship from the University of Paris-Saclay.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Genetic variants in Fukutin related protein (FKRP), an essential enzyme of the glycosylation pathway of  $\alpha$ -dystroglycan, can lead to pathologies with different severities affecting the eye, brain and muscle tissues. Here, we generate an *in vitro* cellular system to characterize the cellular localization as well as the functional potential of the most common *FKRP* patient missense mutations. We observe a differential retention in the Endoplasmic Reticulum (ER), indication of misfolded proteins. We find data supporting that mutant proteins able to overcome this ER-retention through overexpression present functional levels comparable to the wild-type. We also identify a specific region in FKRP protein localized between residues 300 and 321 in which genetic variants found in patients lead to correctly localized proteins but which are nevertheless functionally impaired or catalytically dead in our model, indicating that this particular region might be important for the enzymatic activity of FKRP within the Golgi. Our system thus allows the functional testing of patient specific mutant proteins and the identification of candidate mutants to be further explored with the aim of finding pharmacological treatments targeting the protein quality control system.

## Keywords

FKRP; LGMD2I; dystroglycan; genetic variants; missense mutations; protein quality control; glycosylation.

## 1. Introduction

Muscular dystrophies are a group of monogenic diseases affecting the skeletal muscle and characterized by a progressive loss of the muscle mass. One substantial group of muscle dystrophies termed “dystroglycanopathies” encompasses different genetic pathologies, ultimately characterized by hypoglycosylation of the protein  $\alpha$ -dystroglycan ( $\alpha$ -DG). This protein is a fundamental component of the dystrophin-associated glycoprotein complex (DGC) in the muscles and also plays additional important roles in other tissues such as the eye and brain. Through a complex and specific glycosylation of the protein, raising its weight from 70 to 156 kDa in muscle (Barresi & Campbell, 2006), the plasma membrane is anchored to different extracellular-matrix (ECM) components (Hohenester, Tisi, Talts, & Timpl, 1999; Talts, Andac, Gohring, Brancaccio, & Timpl, 1999; Tisi, Talts, Timpl, & Hohenester, 2000), such as laminin in the cardiac and skeletal muscles (Ervasti & Campbell, 1993). The connexion of the fibers to the ECM is crucial for membrane stabilization, especially during muscle contraction/relaxation cycles. In dystroglycanopathies, hypoglycosylation of  $\alpha$ -DG leads to disruption of plasma membrane attachment, to fragility of the tissue and therefore to a dystrophic process.

The genetic basis of dystroglycanopathies is very heterogeneous, reflecting the peculiar machinery of enzymes contributing to the glycosylation of  $\alpha$ -DG. At present, genetic variants in 17 different genes coding for enzymes of the  $\alpha$ -DG glycosylation pathway have been identified as being implicated in these disorders, which range from the severe Walker-Warburg Syndrome (WWS), Muscle-Eye-Brain disease (MEB) or Congenital Muscular Dystrophy (CMD) to the mildest Limb-Girdle Muscular Dystrophies (LGMDs).

1  
2  
3 Genetic variants in the gene coding for Fukutin-related protein (*FKRP*) (FKRP; MIM#  
4 606596), one of the enzymes of the  $\alpha$ -DG glycosylation pathway, can lead to all the  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Genetic variants in the gene coding for Fukutin-related protein (*FKRP*) (FKRP; MIM# 606596), one of the enzymes of the  $\alpha$ -DG glycosylation pathway, can lead to all the aforementioned pathologies (MIM# 613153, 606612, 607155) (Beltran-Valero de Bernabe, 2004; Brockington et al., 2001; Richard, Laurent, Cirak, & Vissing, 2016). FKRP protein is a type II transmembrane protein localized in the *mid/trans*-Golgi apparatus of the skeletal muscle cells (Alhamidi et al., 2011). It is characterized by a short cytoplasmic domain followed by transmembrane, stem and catalytic domains, the last one possessing a DxD amino-acid motif critical for the catalytic function of the protein (Esapa et al., 2002). FKRP was described as a transferase of ribitol-phosphate into the growing glycosylation chain using as substrate the precursor molecule CDP-ribitol, and acting in succession to another related enzyme of the pathway, Fukutin (*FKTN*) (FKTN; MIM# 607440) (Gerin et al., 2016; Kanagawa et al., 2016). Of note, FKRP and FKTN were recently shown to act also as a CDP-glycerol transferases, which inhibits the functional glycosylation of  $\alpha$ -DG (Imae et al., 2018).

The most common types of *FKRP* patient genetic variants are missense mutations, with, in particular, a high prevalence of a specific genetic variant, the NM\_001039885.2:p.Leu276Ile (L276I) (Richard et al., 2016). Missense mutations, resulting in an amino-acid change, can lead to protein folding defects when the amino-acid properties are not preserved. These misfolded proteins can be detected and blocked by the quality control (QC) system of the cells and, specifically in the case of transmembrane and secretory proteins, be retained in the Endoplasmic reticulum (ER) and directed to premature degradation by the proteasome through the ER-associated degradation (ERAD) system. Interestingly, despite the presence of the genetic variant, a certain degree of biological activity of the protein can still be preserved, suggesting that “rescue” of these proteins from the strict QC surveillance and degradation systems could ameliorate the related pathology. Indeed, pharmacological treatments proved

1  
2  
3 successful *in vitro* for the rescue of FKTN (Tachikawa, Kanagawa, Yu, Kobayashi, & Toda,  
4 2012) or of other mutated proteins of the DGC such as the sarcoglycans (Carotti et al., 2018;  
5 Soheili et al., 2012). Some of the most prevalent *FKRP* missense mutations have been  
6 described to be retained in the ER (Esapa et al., 2002; Esapa, McIlhinney, & Blake, 2005;  
7 Keramaris-Vrantsis et al., 2007; Matsumoto et al., 2004; Torelli et al., 2005), leading to loss  
8 of function though cellular mislocalization from the Golgi, the cellular compartment where  
9 FKRP exerts its function. The functional potential of these ER-retained mutant proteins if  
10 properly rescued to the Golgi has not been assessed, a crucial characteristic to determine at  
11 the time when pharmacological treatments aiming to target the ERQC and ERAD systems are  
12 envisaged for patients. Beside these cases, other *FKRP* genetic variants were shown to be  
13 correctly localized in the Golgi compartment, some of which being implicated in severe  
14 phenotypes such as WWS (Keramaris-Vrantsis et al., 2007). The underlying explanation of  
15 the discrepancies between the correct localization and the severity of the phenotype has not  
16 been elucidated.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36 In this study, we addressed the current gap in knowledge about the functional potential of  
37 mutant proteins bearing some of the most common *FKRP* patient genetic variants. We  
38 developed heterologous models, which permitted the investigation of the subcellular  
39 localization and functional status of the disease-causing FKRP mutated proteins. We  
40 demonstrated that genetic variants observed to be retained in the ER can nevertheless be able  
41 to overcome this retention and present activity levels comparable to wild-type. In addition, we  
42 observed that some of the FKRP mutant proteins that correctly localize in the Golgi present  
43 either no or severely impaired function, indicating that the pathological mechanism of these  
44 *FKRP* genetic variants might correspond to a direct perturbation of the enzymatic function  
45 whereas the mutated protein is considered normal by the QC. Taken together, this data can  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

bring important implications for the development of therapeutic strategies in FKRP deficiencies for which there is still no curative treatment, more specifically for patients affected by genetic variants leading to ER-retained but nonetheless functional proteins.

## 2. Materials and methods

**2.1 Cloning and mutagenesis.** The FKRP fusion protein comprising the human *FKRP* CCDS (Gene ID: 79147, NM\_001039885.2, CCDS12691.1), the prototypical FLAG sequence (DYKDDDDK), a flexible type linker (3xGGGGS) (Chen, Zaro, & Shen, 2013) and a mCherry fluorescent reporter sequence was synthesized and codon-optimized for human expression by GENEWIZ. The transgene was inserted into a lentivirus backbone plasmid under the transcriptional control of the CMV promoter. The final construct was named FKRPmCh. Mutagenesis was performed in FKRPmCh plasmid using the QuickChange XL Mutagenesis Kit (Agilent) according to the supplier's protocol with the mutant constructs differing from the wild-type only by the modification of the codon of the genetic variant.

**2.2 Cell culture.** Near-haploid human HAP1 cells are commercialized by Horizon Discovery™. The HAP1 FKRP<sub>KO</sub> cell line, bearing a 17 base-pair (bp) deletion in the endogenous *FKRP* gene, was available off-the-shelf (Product ID: HZGHC000726c009). The cells were grown in Iscove's Modified Dulbecco's Medium (IMDM) (Thermo Fisher Scientific) with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific) and 10 µg/ml of Gentamicin (Thermo Fisher Scientific) and incubated at 37°C and atmospheric humidity of 5% CO<sub>2</sub>. Cells were mycoplasma negative.

1  
2  
3 **2.3 Transfections and transductions.** Cells were seeded in six or twelve well-plates at 60%  
4  
5 confluence. Cells used for immuno-fluorescence (IF) staining were seeded on glass coverslips  
6  
7 in the bottom of the well. Transfection of FKRPmCh plasmids were conducted using  
8  
9 Turbofectin 8.0 reagent (Origene) for 48h accordingly to the supplier's protocol and a  
10  
11 Turbofectin/DNA ratio of 3: 1 with the same DNA concentrations. Transduction of lentiviral  
12  
13 particles expressing FKRPmCh WT or mutant constructs were performed at multiplicity of  
14  
15 infection (MOI) of three and in combination with Polybrene (6ug/mL; Sigma-Aldrich).  
16  
17 Incubation with the viral particles was performed for 18h at 37°C and 5% CO<sub>2</sub>, after which  
18  
19 the medium was replaced and the cells were kept at 37°C until further analysis.  
20  
21  
22  
23

24  
25 **2.4 Immuno-fluorescence confocal staining, acquisition and analysis.** The IF staining for  
26  
27 confocal microscopy was performed as follows: the cells were fixed in formaldehyde 3.7%  
28  
29 (Sigma-Aldrich) for 15 minutes at room temperature. If permeabilization was required, Triton  
30  
31 X-100 0.5% (Sigma-Aldrich) was used for 5 min at room temperature. Saturation was  
32  
33 performed in PBS 20% foetal bovine serum (FBS) for 1h at room temperature. The primary  
34  
35 antibodies Calnexin (Rabbit, ab22595, Abcam), GM130 (Mouse, 610822, BD-Biosciences),  
36  
37 TGN46 (Sheep, AHP500GT, BioRad),  $\alpha$ -dystroglycan (IIH6; Mouse, sc-53987, Santa Cruz  
38  
39 Biotechnology),  $\beta$ -integrin (Mouse, sc-13590, Santa Cruz Biotechnology) or Wheat Germ  
40  
41 Agglutinin (WGA-Alexa Fluor™ 488 Conjugate, W11261, Thermo Fisher Scientific) were  
42  
43 added in the appropriate dilutions in PBS 2% FBS for 3h at room-temperature or over-night at  
44  
45 4°C. After three washes with PBS for 5 minutes, incubation with secondary antibodies Alexa  
46  
47 Fluor™-488 and Alexa Fluor™-594 fluorescent-conjugated antibodies (Thermo Fisher  
48  
49 Scientific) was performed in PBS 2% FBS for 1h at room-temperature in the dark. Three  
50  
51 washes with PBS for 5 minutes were performed and the glass slides were mounted in DAPI  
52  
53 Fluoromount-G® (CliniSciences) overnight at 4°C. For the endogenous FKRP protein  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 labelling, the fluorescent signal amplification Tyramide SuperBoost Kit (Anti-rabbit Alexa  
4 Fluor™-488, B40922, Thermo Fisher Scientific) was used accordingly to the supplier's  
5 protocol. Confocal images were taken using the Leica SP8 confocal microscope (Leica) at  
6  
7 either the 40X, 63X or 100X oil-objectives. Bright-field images were taken using the Evos  
8 microscope (Thermo Fisher Scientific) at a 40X objective. Images were treated and analysed  
9  
10 using ImageJ/Fiji software (Schindelin et al., 2012) and the Pearson's coefficients of  
11 correlation were calculated using the JACoP plugin (Bolte & Cordelieres, 2006).  
12  
13  
14  
15  
16  
17  
18  
19

20 **2.5 Flow cytometry staining, acquisition and analysis.** The staining for flow cytometry was  
21 performed as follows: saturation was performed in cold PBS 2% FBS + human FcR blocking  
22 agent (Miltenyi Biotec) for 20 minutes at 4°C. The primary antibody  $\alpha$ -dystroglycan (IIH6;  
23 Mouse, sc-53987, Santa Cruz Biotechnology) was diluted at a ratio 1/20 in cold PBS 2% FBS  
24 and incubated for 20 minutes at 4°C. After one wash with cold PBS, incubation with the Goat  
25 anti-Mouse Alexa Fluor™-488 fluorescent-conjugated secondary antibody (Thermo Fisher  
26 Scientific) was performed in PBS 2% FBS for 20 minutes at 4°C in the dark. Three washes  
27 with cold PBS were performed and the final cell pellets were resuspended in cold PBS 2%  
28 FBS and kept in ice until further analysis. Positive (HAP1-WT) and negative (secondary  
29 antibody alone on HAP1- FKRP<sub>KO</sub>) controls were included in all experiments.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 The CytoFLEX flow cytometer (Beckman Coulter) and the B525/40 BP (A488) and Y610/20  
45 BP (mCherry) lasers were used with the same settings for all experiments. Flow cytometry  
46 data was treated and analysed using the Kaluza analysis software (Beckman Coulter). Flow  
47 cytometry values are presented as the integrated Mean Fluorescence Intensity (iMFI). iMFI is  
48 calculated as the MFI multiplied by the percentage of positive cells for the glycosylation  
49 (IIH6) signal within the mCherry positive cell population which equals correctly transfected  
50 cells. The iMFI  $\alpha$ -DG glycosylation values of patient fibroblasts by flow cytometry were  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 shown to be closely related to the glycosylation levels in the corresponding muscle biopsies  
4  
5 (Stevens et al., 2013). Flow cytometry values were normalized against the transduced FKRP  
6  
7 WT construct in each independent experiment.  
8  
9

10  
11 **2.6 Prediction of functional impact of FKRP variants.** The online predictor tools  
12  
13 Polymorphism Phenotyping v2 (PolyPhen-2 (Adzhubei et al., 2010),  
14  
15 <http://genetics.bwh.harvard.edu/pph2/>), Protein Variation Effect Analyzer (PROVEAN (Choi,  
16  
17 Sims, Murphy, Miller, & Chan, 2012), [http://provean.jcvi.org/seq\\_submit.php](http://provean.jcvi.org/seq_submit.php)) and  
18  
19 MutationAssessor release 3 ((Reva, Antipin, & Sander, 2011), <http://mutationassessor.org/r3/>)  
20  
21 were used at the last current version (March 2019) and run with the default settings.  
22  
23  
24  
25

26  
27 **2.7 Data and statistical analysis.** The GraphPad PRISM 7.01 program (GraphPad Software  
28  
29 Inc.) was used for calculating statistics using unpaired t-test. The results represent the average  
30  
31  $\pm$  SEM of at least three independent experiments (cell culture, transfection/transduction and  
32  
33 analysis performed in different days). P-values were calculated using the WT as control and P  
34  
35  $<0.05$ . Regression curves were calculated using a centred second order polynomial (quadratic)  
36  
37 equation with ordinary fit parameters. ns= non-significant, \*p  $\leq 0.05$ , \*\*p  $\leq 0.01$ , \*\*\*p  $\leq 0.001$ ,  
38  
39 \*\*\*\*p  $\leq 0.0001$ .  
40  
41  
42  
43  
44  
45  
46

## 47 **3. Results**

### 48 **3.1 Cellular model validation**

49  
50  
51  
52  
53  
54 In order to study the cellular consequences of FKRP patient genetic variants *in vitro*, we took  
55  
56 advantage of the near-haploid HAP1 cell line as these cells were previously shown to support  
57  
58  
59  
60

1  
2  
3 the complete  $\alpha$ -DG chain of glycosylation (Endo et al., 2015; Riemersma et al., 2015). To  
4 avoid interference by the endogenous FKRP protein, a CRISPR/Cas9-induced FKRP knock-  
5 out (KO) cell line was used (HAP1-FKRP<sub>KO</sub>). Validation of the cellular model was performed  
6 by FKRP immuno-labelling and  $\alpha$ -DG glycosylation staining. Using an immuno-fluorescence  
7 (IF) amplification system, we demonstrated the absence of endogenous FKRP protein in the  
8 HAP1-FKRP<sub>KO</sub> cells whereas the signal co-localized with the Golgi markers (GM130 and  
9 TGN46 for *cis*- and *trans*-Golgi respectively) in the HAP1-WT cell line as expected (Figure  
10 1A). The HAP1-FKRP<sub>KO</sub> cell line, while presenting normal cell growth, was characterized by  
11 small cytoplasmic volume and membrane disturbances, specifically deficiency in filipodia, as  
12 detected by membrane staining for  $\beta$ -integrin and Wheat Germ Agglutinin (WGA) (Figure  
13 1B). IF and flow-cytometry analysis showed a substantial reduction of the functional  $\alpha$ -DG  
14 glycosylation at the cell membrane based on the IIH6 specific antibody (Figure 1C),  
15 confirming the absence of FKRP activity in HAP1-FKRP<sub>KO</sub> cells and the utility of using this  
16 cell line for FKRP mutant protein characterization.

17  
18  
19 To be able to select the exogenous FKRP positive cells in flow cytometry experiments and to  
20 directly detect the protein in cellular localization experiments without the need of antibodies,  
21 we generated a fluorescently labelled fusion protein. This protein consists of the human *FKRP*  
22 coding sequence fused, at its C-terminus and through a flexible linker, to a mCherry (mCh)  
23 fluorescent reporter protein (FKRPMCh). IF staining experiments demonstrated the integrity  
24 of the fusion protein since the mCherry signal co-localized with the labelling for FKRP and  
25 with the *trans*-Golgi marker TGN46 (Supp. Figures S1A and S1B). In addition, only the  
26 mCherry positive cells were positive for membrane staining with the IIH6 antibody in non-  
27 permeabilized conditions (Supp. Figure S1C), indicating that the addition of the fluorescent  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 reporter did not alter the normal cellular localization and function of the WT FKRP protein  
4  
5 and that the construct could be used further for genetic variants characterization.  
6  
7

### 8 **3.2 Cellular localization of FKRP mutant proteins**

9  
10  
11 With the aim of characterizing FKRP mutant proteins using our overexpression system, we  
12  
13 chose to test seven missense patient genetic variants associated with pathologies ranging from  
14  
15 the severe CMD to the mild LGMD2I and localized throughout the entire length of the protein  
16  
17 (Table 1A). In addition to the patient genetic variants, two control mutants were used. In the  
18  
19 first, the di-Arginine (R) motif at positions 2 and 5 (R2R5) responsible for the Golgi  
20  
21 positioning was mutated to Glutamic acid (E) residues (E2E5). In the second, the catalytic  
22  
23 residues composed of two Aspartic acids (D) and a Valine (V) in positions 362-364 (DvD)  
24  
25 were mutated into asparagine residues (N) (NNN). The first mutant protein was previously  
26  
27 described as being unable to traffic from the ER to the Golgi, whereas the second was shown  
28  
29 to abrogate the enzymatic activity of FKRP (Esapa et al., 2002).  
30  
31  
32  
33  
34  
35

36 When overexpressed in HAP1-FKRP<sub>KO</sub> cells, the different constructs presented three different  
37  
38 profiles. The WT construct co-localized with the *trans*-Golgi, as well as the L276I,  
39  
40 NM\_001039885.2:p.Tyr182Cys (Y182C) and NM\_001039885.2:p.Val300Ala (V300A)  
41  
42 mutant proteins (Figure 2A). The mCherry signal of the E2E5 and  
43  
44 NM\_001039885.2:p.Val405Leu (V405L) mutants presented a cytoplasmic localization, later  
45  
46 confirmed to co-localize with the ER marker calnexin (CNX) (Supp. Figure S2). Finally, we  
47  
48 observed a dual ER/Golgi co-localization for the NNN, NM\_001039885.2:p.Ser221Arg  
49  
50 (S221R), NM\_001039885.2:p.Pro448Leu (P448L) and NM\_001039885.2:p.Ala455Asp  
51  
52 (A455D) mutant proteins, indicating that these proteins were retained in the ER but were  
53  
54 nevertheless able to overcome this retention. Overall, we concluded that, in our system, some  
55  
56  
57  
58  
59  
60

1  
2  
3 genetic variants lead to different levels of ER-retention but that evasion from this system is  
4 possible for a number of these mutant proteins.  
5  
6  
7

### 8 **3.3 Functional analysis of FKRP mutant proteins**

9  
10  
11 Given that some mutants were co-localized in the Golgi, we tested their protein level and  
12 potential for functionality by flow-cytometry using the mCherry and glycosylation signals,  
13 respectively (Supp. Figure S3). We observed that the amount of FKRPmCh protein steadily  
14 increased as in the WT for all mutants with the exception of the E2E5, V405L and A455D  
15 mutants, suggesting that the presence of the genetic variant may lead to protein instability  
16 (Figure 2B). As expected, the increase of FKRPmCh amount was associated with an increase  
17 in  $\alpha$ -DG functional glycosylation for the WT in the mCherry positive population. The Y182C  
18 and L276I mutants led to the same glycosylation levels than the WT, demonstrating a fully  
19 functional capacity, whereas the S221R, P448L and A455D, although displaying a slower  
20 increase, soon caught up with WT functional levels at 45h (Supp. Figure S4). The reduced  
21 level of glycosylation observed for the V405L is probably related to the low level of the  
22 protein. The NNN mutant control was functionally fully impaired as predicted since  
23 corresponding to a catalytically dead enzyme while the E2E5 mutant displayed a marked  
24 functional reduction most likely due to the impaired traffic to the Golgi compartment as  
25 demonstrated in the IF staining. Remarkably, the V300A mutant protein, which was correctly  
26 localized in the Golgi apparatus, displayed a striking reduced level of glycosylation,  
27 indicating that, although the protein is able to traffic correctly, it fails to extend the  $\alpha$ -DG  
28 glycosylation moiety. Taken together, our results showed that overexpression of FKRP  
29 mutant proteins in the HAP1-FKRP<sub>KO</sub> cell line can be used to study the localization and the  
30 function potential of FKRP mutant proteins. Additionally, we showed that characterization of  
31 cellular localization alone is not sufficient to infer protein function.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 3.4 Characterization of *FKRP* patient genetic variants localized between residues 300 and 328

We were intrigued about the functional impairment induced by V300A, which is located at the beginning of the predicted catalytic domain (Alhamidi et al., 2011). The corresponding mutant protein did not present signs of ER-retention nor was its protein level low by flow cytometry, indicating that the protein was not identified by the QC/ERAD systems as misfolded. Yet, this protein was not able to function properly, i.e. glycosylation of  $\alpha$ -DG, despite the mutated residue not being localized in the DvD catalytic core residues (positions 362-364). We decided to investigate further the cellular localization and function of other genetic variants positioned downstream of the 300 Valine residue and in the beginning of the catalytic domain based on the published *FKRP* model (Alhamidi et al., 2011). For this purpose, we generated 14 additional patient genetic variants present between residues 300 and 328 of the *FKRP* protein (Table 1B). Our mutant panel included NM\_001039885.2:p.Tyr307Asn (Y307N) and NM\_001039885.2:p.Cys318Tyr (C318Y), previously characterized to be localized in the Golgi in other cell types (Dolatshad et al., 2005; Torelli et al., 2005). The associated phenotypes encompassed all severities, with the majority of genetic variants being reported in the Leiden Muscular Dystrophy database only one or two times.

The IF staining demonstrated that, alike the V300A mutant, all these additional *FKRP* mutant proteins, to the exception of the NM\_001039885.2:p.Tyr328Ser (Y328S), co-localized with the Golgi apparatus (Figure 3A). Regarding protein function, all the tested genetic variants presented reduced levels of function compared with the WT (Figure 3B), with four mutants, NM\_001039885.2:(p.Pro305Leu (P305L), Y307N, NM\_001039885.2:p.Thr314Pro (T314P) and C318Y presenting functional levels close to the catalytically dead NNN mutant. We could

1  
2  
3 also observe that the nature of the amino-acid modification, in addition to the amino-acid  
4 position, also impacted the function, as the same Threonine (T) residue in position 314, when  
5 modified to a Methionine (M) was still functional where modification to a Proline (P)  
6 abrogated completely the function. The modification of the Proline (P) in position 316 to  
7 either Arginine (R), Serine (S) or Threonine (T) did not change dramatically the overall  
8 function. All these results indicated that missense mutations localized between residues 300 to  
9 321 of the human FKRP protein, and which we refer to FKRP<sub>300-321</sub> region, do not seem to  
10 induce ER-retention but nevertheless give rise to non-functional or severely impaired mutant  
11 proteins in our system. Moreover, four genetic variants abrogated completely the protein  
12 function, perhaps indicative of the importance of these residues for the protein activity.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

## 31 **4. Discussion**

32  
33  
34 In this study, we evaluated the cellular localization, as well as the level of activity of FKRP  
35 proteins bearing genetic variants commonly found in patients using an overexpression system  
36 based on the HAP1 FKRP<sub>KO</sub> cell line. In this model system, we identified one genetic variant,  
37 V405L, which leads to a strict ER localization. Interestingly, this change between the two  
38 aliphatic amino acids is quite conservative and is not predicted to overly disrupt the secondary  
39 structure of the protein. It is therefore possible that the consequence will pertain on the  
40 tertiary or quaternary structure or else the corresponding residue is important for association  
41 with a protein implicated in the trafficking to the Golgi. We also identified three mutant  
42 proteins, S221R, P448L and A455D, found to be retained in the ER but which were  
43 nevertheless able to overcome this retention when overexpressed. This “leakage effect” has  
44 been previously described and seen in other misfolded proteins (Gomez-Navarro & Miller,  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 2016; Kawaguchi, Hsu, & Ng, 2010). Interestingly, these three mutants displayed normal  
4 functional levels. Additional mutants that were purely Golgi-resident presented different  
5 degrees of defect in enzymatic activity, with a few of them being enzymatically dead (P305L,  
6 Y307N, T314P and C318Y), indicating that this particular region might be important for the  
7 enzymatic activity of FKR<sub>P</sub> within the Golgi. Finally, some mutants behave similarly to the  
8 WT protein (Y182C and L276I) with respect to localization in the Golgi and  
9 glycosyltransferase function in our system.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20 The result obtained with the most frequent *FKRP* genetic variant L276I, which is well known  
21 to be associated with the mildest form of the disease, clearly pinpoints to one of the  
22 limitations of our cellular system. Here, the corresponding mutant is undistinguishable to WT  
23 whereas we previously showed that it presents a defect in glycosylation function *in vivo*  
24 (Gicquel et al., 2017). Clearly, the high overexpression levels, leading to the exacerbated  
25 protein escape from the ER into the Golgi, may not allow the observation of subtle differences  
26 induced by this type of genetic variants. We might postulate that the L276I, as well as the  
27 Y182C mutant protein, may require extended folding times and be less readily available for  
28 the glycosylation process in skeletal muscle context. This hypothesis is supported by the fact  
29 that the L276I mutant protein was seen to interact more strongly with CNX, a molecular  
30 chaperone of the ER, than the WT (Esapa et al., 2005).

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46 Our data indicates that it is possible to obtain a full functionality with overexpression of  
47 proteins that are recognized as being abnormal by the QC as demonstrated by their ER  
48 localization. A recent report demonstrated the correct function of the P488L mutant protein *in*  
49 *vivo* (Tucker, Lu, Xiao, & Lu, 2018). The authors showed that the mutant protein was able to  
50 restore the  $\alpha$ -DG glycosylation at the muscle membrane and correction of the dystrophic  
51 phenotype when overexpressed by adeno-associated virus (AAV) injection in a P448L<sup>neo</sup>-  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 mouse model. In addition, in a more recent study, the same group showed that  
4  
5 supplementation of ribitol in drinking water of the P448L<sup>neo-</sup> mouse increased  $\alpha$ -DG  
6  
7 glycosylation (Cataldi, Lu, Blaeser, & Lu, 2018), indicating that even the endogenous P448L  
8  
9 mutant protein present in the mice might still retain some level of functionality. Altogether,  
10  
11 these different pieces of evidence support the idea that a pharmacological strategy allowing a  
12  
13 bypass of the QC might lead to a therapeutic benefit for patients with the corresponding  
14  
15 genetic variants.  
16  
17  
18  
19

20 Our findings also revealed that patient genetic variants localized within the FKRP<sub>300-321</sub> region  
21  
22 of the protein, remarkably are all correctly localized in the Golgi but correspond to  
23  
24 functionally impaired proteins in our cellular model. Their correct localization indicates that,  
25  
26 after protein folding in the ER, the structure of these mutant proteins is possibly qualified as  
27  
28 being correctly folded by the QC system and the proteins are allowed to proceed further  
29  
30 towards their final destination. However, once in the Golgi, they might not have or fail to  
31  
32 attain the necessary features for proper function. One can think of incorrect localization  
33  
34 within the Golgi apparatus, impossibility to reach an active conformation or dimerization, or  
35  
36 impaired interaction with the substrate, the  $\alpha$ -DG glycosylation growing chain or additional  
37  
38 partners such as FKTN or Transmembrane Protein 5 (TMEM5) protein (Alhamidi et al.,  
39  
40 2011; Nishihara et al., 2018). The family of glycosyltransferases (GTs), of which FKRP is a  
41  
42 member, encompass enzymes responsible for the transfer of sugar moieties and the formation  
43  
44 of glycosidic linkages (Lairson, Henrissat, Davies, & Withers, 2008). The consensus in the  
45  
46 field is that the nucleotide-binding residues of GTs are not restricted to the characteristic DxD  
47  
48 motif, but can be also extended to amino-acids localized upstream and downstream of this  
49  
50 region (Breton & Imberty, 1999). While the FKRP<sub>300-321</sub> area is not close to the catalytic DxD  
51  
52 motif when the amino-acid linear sequence is considered, it is conceivable that this region is  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 required for the catalytic function and participate in the catalytic pocket through the 3D  
4 conformation. Despite our attempt, no parallel between the prediction of the deleterious score  
5 by online predictors and the severity of the disease caused by the FKRP variants was noted  
6  
7 (Supp. Table S1). Likewise, no relevant tri-dimensional model was achieved since the results  
8  
9 obtained with different prediction softwares were inconsistent. A crystallography model of  
10  
11 FKRP protein is then crucial for better understanding the mechanism of enzymatic activation  
12  
13 and function and shed a light on the structural consequences arising from the mutated  
14  
15 residues. Interestingly, to the exception of the P305L mutant which is associated to an LGMD  
16  
17 phenotype, all the identified catalytically “dead” genetic variants are associated with severe  
18  
19 phenotypes such as MEB/CMD, LIS and WWS. This information is in support of our findings  
20  
21 for the severely impaired function of these mutated proteins and might indicate that a similar  
22  
23 phenotype would be present in the human tissue context. Furthermore, patient genetic variants  
24  
25 in *FKTN*, the FKRP homologous protein that shares the same substrate and activity, were  
26  
27 described to be correctly localized in the Golgi (Tachikawa et al., 2012) while being  
28  
29 functionally impaired, (Kanagawa et al., 2016), reinforcing the relevance of our results.  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 In conclusion, we propose the following scenario of fate of the different FKRP protein  
40  
41 variants, suggesting the absence of correlation between the subcellular localization and  
42  
43 function of the mutant proteins (Figure 4). Overall, we believe that our experimental  
44  
45 approach, integrating the information on the mutant protein cellular localization with its  
46  
47 function, contributes for the complete understanding of the pathogenic impact of the patient  
48  
49 mutation and of the function of the protein. Indeed, we might have uncovered a particular  
50  
51 region outside the catalytic motif that seems important for the enzymatic activity of FKRP  
52  
53 within the Golgi. Unfortunately, it is difficult to make any conclusions about the severity of  
54  
55 the disease based solely on the results obtained in our cellular model. It is highly probable that  
56  
57  
58  
59  
60

1  
2  
3 additional factors intervene to explain the phenotype of the variants or combinations of  
4 variants. Lastly, the demonstration that the alteration of one amino acid interfering with the  
5 proper protein folding process might nevertheless lead to a protein with functionality can lead  
6 to further studies about the potential for the rescue of such proteins from degradation as a  
7 treatment option for patients.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

## 19 **Acknowledgments**

20  
21  
22  
23 We would like to thank all the Progressive Muscular Dystrophies group members. We are  
24 grateful to the “Imaging and Cytometry Core Facility” of Généthon for technical support and  
25 to Genopole Research, Evry, for the purchase of the equipment. The authors have no conflict  
26 of interest to declare.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., . . . Sunyaev, S. R. (2010). A method and server for predicting damaging missense mutations. *Nat Methods*, 7(4), 248-249. doi: 10.1038/nmeth0410-248
- Alhamidi, M., Kjeldsen Buvang, E., Fagerheim, T., Brox, V., Lindal, S., Van Ghelue, M., & Nilssen, O. (2011). Fukutin-related protein resides in the Golgi cisternae of skeletal muscle fibres and forms disulfide-linked homodimers via an N-terminal interaction. *PLoS One*, 6(8), e22968. doi: 10.1371/journal.pone.0022968
- Barresi, R., & Campbell, K. P. (2006). Dystroglycan: from biosynthesis to pathogenesis of human disease. *J Cell Sci*, 119(Pt 2), 199-207.
- Beltran-Valero de Bernabe, D. (2004). Mutations in the FKRPs gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. *Journal of Medical Genetics*, 41(5), e61-e61. doi: 10.1136/jmg.2003.013870
- Bolte, S., & Cordelieres, F. P. (2006). A guided tour into subcellular colocalization analysis in light microscopy. *J Microsc*, 224(Pt 3), 213-232. doi: 10.1111/j.1365-2818.2006.01706.x
- Bouchet, C., Gonzales, M., Vuillaumier-Barrot, S., Devisme, L., Lebizec, C., Alanio, E., . . . Seta, N. (2007). Molecular heterogeneity in fetal forms of type II lissencephaly. *Hum Mutat*, 28(10), 1020-1027. doi: 10.1002/humu.20561
- Breton, C., & Imberty, A. (1999). Structure/function studies of glycosyltransferases. *Curr Opin Struct Biol*, 9(5), 563-571.
- Brockington, M., Blake, D. J., Prandini, P., Brown, S. C., Torelli, S., Benson, M. A., . . . Muntoni, F. (2001). Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. [Case Reports  
Research Support, Non-U.S. Gov't]. *Am J Hum Genet*, 69(6), 1198-1209. doi: 10.1086/324412
- Carotti, M., Marsolier, J., Soardi, M., Bianchini, E., Gomiero, C., Fecchio, C., . . . Sandona, D. (2018). Repairing folding-defective alpha-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D. *Hum Mol Genet*, 27(6), 969-984. doi: 10.1093/hmg/ddy013
- Cataldi, M. P., Lu, P., Blaeser, A., & Lu, Q. L. (2018). Ribitol restores functionally glycosylated alpha-dystroglycan and improves muscle function in dystrophic FKRPs-mutant mice. *Nat Commun*, 9(1), 3448. doi: 10.1038/s41467-018-05990-z

- 1  
2  
3 Chen, X., Zaro, J. L., & Shen, W. C. (2013). Fusion protein linkers: property, design and  
4 functionality. *Adv Drug Deliv Rev*, 65(10), 1357-1369. doi:  
5 10.1016/j.addr.2012.09.039  
6  
7  
8 Choi, Y., Sims, G. E., Murphy, S., Miller, J. R., & Chan, A. P. (2012). Predicting the  
9 functional effect of amino acid substitutions and indels. *PLoS One*, 7(10), e46688. doi:  
10 10.1371/journal.pone.0046688  
11  
12 de Paula, F., Vieira, N., Starling, A., Yamamoto, L. U., Lima, B., de Cassia Pavanello, R., . . .  
13 Zatz, M. (2003). Asymptomatic carriers for homozygous novel mutations in the FKRP  
14 gene: the other end of the spectrum. *Eur J Hum Genet*, 11(12), 923-930. doi:  
15 10.1038/sj.ejhg.5201066  
16  
17 Dolatshad, N. F., Brockington, M., Torelli, S., Skordis, L., Wever, U., Wells, D. J., . . .  
18 Brown, S. C. (2005). Mutated fukutin-related protein (FKRP) localises as wild type in  
19 differentiated muscle cells. [Research Support, Non-U.S. Gov't]. *Exp Cell Res*, 309(2),  
20 370-378. doi: 10.1016/j.yexcr.2005.06.017  
21  
22  
23 Endo, Y., Dong, M., Noguchi, S., Ogawa, M., Hayashi, Y. K., Kuru, S., . . . Nishino, I.  
24 (2015). Milder forms of muscular dystrophy associated with POMGNT2 mutations.  
25 *Neurol Genet*, 1(4), e33. doi: 10.1212/nxg.0000000000000033  
26  
27  
28 Ervasti, J. M., & Campbell, K. P. (1993). A role for the dystrophin-glycoprotein complex as a  
29 transmembrane linker between laminin and actin. *J Cell Biol*, 122(4), 809-823.  
30  
31 Esapa, C. T., Benson, M. A., Schroder, J. E., Martin-Rendon, E., Brockington, M., Brown, S.  
32 C., . . . Blake, D. J. (2002). Functional requirements for fukutin-related protein in the  
33 Golgi apparatus. *Hum Mol Genet*, 11(26), 3319-3331.  
34  
35 Esapa, C. T., McIlhinney, R. A., & Blake, D. J. (2005). Fukutin-related protein mutations that  
36 cause congenital muscular dystrophy result in ER-retention of the mutant protein in  
37 cultured cells. *Hum Mol Genet*, 14(2), 295-305. doi: 10.1093/hmg/ddi026  
38  
39  
40 Gerin, I., Ury, B., Breloy, I., Bouchet-Seraphin, C., Bolsee, J., Halbout, M., . . . Bommer, G.  
41 T. (2016). ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol  
42 phosphate onto alpha-dystroglycan. *Nat Commun*, 7, 11534. doi:  
43 10.1038/ncomms11534  
44  
45  
46 Gicquel, E., Maizonnier, N., Foltz, S. J., Martin, W. J., Bourg, N., Svinartchouk, F., . . .  
47 Richard, I. (2017). AAV-mediated transfer of FKRP shows therapeutic efficacy in a  
48 murine model but requires control of gene expression. *Hum Mol Genet*, 26(10), 1952-  
49 1965. doi: 10.1093/hmg/ddx066  
50  
51  
52 Gomez-Navarro, N., & Miller, E. (2016). Protein sorting at the ER-Golgi interface. *J Cell*  
53 *Biol*, 215(6), 769-778. doi: 10.1083/jcb.201610031  
54  
55  
56 Guglieri, M., Straub, V., Bushby, K., & Lochmuller, H. (2008). Limb-girdle muscular  
57 dystrophies. *Curr Opin Neurol*, 21(5), 576-584. doi:  
58 10.1097/WCO.0b013e32830efdc2  
59  
60

- 1  
2  
3 Hohenester, E., Tisi, D., Talts, J. F., & Timpl, R. (1999). The crystal structure of a laminin G-  
4 like module reveals the molecular basis of alpha-dystroglycan binding to laminins,  
5 perlecan, and agrin. [Research Support, Non-U.S. Gov't]. *Mol Cell*, *4*(5), 783-792.  
6  
7 Imae, R., Manya, H., Tsumoto, H., Osumi, K., Tanaka, T., Mizuno, M., . . . Endo, T. (2018).  
8 CDP-glycerol inhibits the synthesis of the functional O-mannosyl glycan of alpha-  
9 dystroglycan. *J Biol Chem*, *293*(31), 12186-12198. doi: 10.1074/jbc.RA118.003197  
10  
11  
12 Kanagawa, M., Kobayashi, K., Tajiri, M., Manya, H., Kuga, A., Yamaguchi, Y., . . . Toda, T.  
13 (2016). Identification of a Post-translational Modification with Ribitol-Phosphate and  
14 Its Defect in Muscular Dystrophy. *Cell Rep*, *14*(9), 2209-2223. doi:  
15 10.1016/j.celrep.2016.02.017  
16  
17 Kawaguchi, S., Hsu, C. L., & Ng, D. T. (2010). Interplay of substrate retention and export  
18 signals in endoplasmic reticulum quality control. *PLoS One*, *5*(11), e15532. doi:  
19 10.1371/journal.pone.0015532  
20  
21  
22 Kefi, M., Amouri, R., Chabrak, S., Mechmeche, R., & Hentati, F. (2008). Variable cardiac  
23 involvement in Tunisian siblings harboring FKRП gene mutations. *Neuropediatrics*,  
24 *39*(2), 113-115. doi: 10.1055/s-2008-1081465  
25  
26 Keramaris-Vrantsis, E., Lu, P. J., Doran, T., Zillmer, A., Ashar, J., Esapa, C. T., . . . Lu, Q. L.  
27 (2007). Fukutin-related protein localizes to the Golgi apparatus and mutations lead to  
28 mislocalization in muscle in vivo. [Research Support, Non-U.S. Gov't]. *Muscle Nerve*,  
29 *36*(4), 455-465. doi: 10.1002/mus.20833  
30  
31  
32 Lairson, L. L., Henrissat, B., Davies, G. J., & Withers, S. G. (2008). Glycosyltransferases:  
33 structures, functions, and mechanisms. *Annu Rev Biochem*, *77*, 521-555. doi:  
34 10.1146/annurev.biochem.76.061005.092322  
35  
36  
37 Louhichi, N., Triki, C., Quijano-Roy, S., Richard, P., Makri, S., Meziou, M., . . . Fakhfakh, F.  
38 (2004). New FKRП mutations causing congenital muscular dystrophy associated with  
39 mental retardation and central nervous system abnormalities. Identification of a  
40 founder mutation in Tunisian families. *Neurogenetics*, *5*(1), 27-34. doi:  
41 10.1007/s10048-003-0165-9  
42  
43  
44 Matsumoto, H., Noguchi, S., Sugie, K., Ogawa, M., Murayama, K., Hayashi, Y. K., &  
45 Nishino, I. (2004). Subcellular localization of fukutin and fukutin-related protein in  
46 muscle cells. [Research Support, Non-U.S. Gov't]. *J Biochem*, *135*(6), 709-712. doi:  
47 10.1093/jb/mvh086  
48  
49 Mercuri, E., Brockington, M., Straub, V., Quijano-Roy, S., Yuva, Y., Herrmann, R., . . .  
50 Muntoni, F. (2003). Phenotypic spectrum associated with mutations in the fukutin-  
51 related protein gene. *Ann Neurol*, *53*(4), 537-542. doi: 10.1002/ana.10559  
52  
53  
54 Mercuri, E., Topaloglu, H., Brockington, M., Berardinelli, A., Pichiecchio, A., Santorelli, F., .  
55 . . . Muntoni, F. (2006). Spectrum of brain changes in patients with congenital muscular  
56 dystrophy and FKRП gene mutations. *Arch Neurol*, *63*(2), 251-257. doi:  
57 10.1001/archneur.63.2.251  
58  
59  
60

- 1  
2  
3 Nishihara, R., Kobayashi, K., Imae, R., Tsumoto, H., Manya, H., Mizuno, M., . . . Toda, T.  
4 (2018). Cell endogenous activities of fukutin and FKRPs coexist with the ribitol  
5 xylosyltransferase, TMEM5. *Biochem Biophys Res Commun*, 497(4), 1025-1030. doi:  
6 10.1016/j.bbrc.2018.02.162  
7  
8  
9 Quijano-Roy, S., Marti-Carrera, I., Makri, S., Mayer, M., Maugenre, S., Richard, P., . . .  
10 Carlier, R. Y. (2006). Brain MRI abnormalities in muscular dystrophy due to FKRPs  
11 mutations. *Brain Dev*, 28(4), 232-242. doi: 10.1016/j.braindev.2005.08.003  
12  
13 Reva, B., Antipin, Y., & Sander, C. (2011). Predicting the functional impact of protein  
14 mutations: application to cancer genomics. *Nucleic Acids Res*, 39(17), e118. doi:  
15 10.1093/nar/gkr407  
16  
17 Richard, I., Laurent, J. P., Cirak, S., & Vissing, J. (2016). 216th ENMC international  
18 workshop: Clinical readiness in FKRPs related myopathies January 15-17, 2016  
19 Naarden, The Netherlands. *Neuromuscul Disord*, 26(10), 717-724. doi:  
20 10.1016/j.nmd.2016.08.012  
21  
22  
23 Riemersma, M., Froese, D. S., van Tol, W., Engelke, U. F., Kopec, J., van Scherpenzeel, M., .  
24 . . . Lefeber, D. J. (2015). Human ISPD Is a Cytidyltransferase Required for  
25 Dystroglycan O-Mannosylation. [Research Support, Non-U.S. Gov't]. *Chem Biol*,  
26 22(12), 1643-1652. doi: 10.1016/j.chembiol.2015.10.014  
27  
28  
29 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., . . .  
30 Cardona, A. (2012). Fiji: an open-source platform for biological-image analysis. *Nat*  
31 *Methods*, 9(7), 676-682. doi: 10.1038/nmeth.2019  
32  
33 Soheili, T., Gicquel, E., Poupiot, J., N'Guyen, L., Le Roy, F., Bartoli, M., & Richard, I.  
34 (2012). Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum  
35 quality control is associated with minimal structural modifications. *Hum Mutat*, 33(2),  
36 429-439. doi: 10.1002/humu.21659  
37  
38  
39 Stevens, E., Torelli, S., Feng, L., Phadke, R., Walter, M. C., Schneiderat, P., . . . Muntoni, F.  
40 (2013). Flow cytometry for the analysis of alpha-dystroglycan glycosylation in  
41 fibroblasts from patients with dystroglycanopathies. *PLoS One*, 8(7), e68958. doi:  
42 10.1371/journal.pone.0068958  
43  
44  
45 Tachikawa, M., Kanagawa, M., Yu, C. C., Kobayashi, K., & Toda, T. (2012). Mislocalization  
46 of fukutin protein by disease-causing missense mutations can be rescued with  
47 treatments directed at folding amelioration. [Research Support, Non-U.S. Gov't]. *J*  
48 *Biol Chem*, 287(11), 8398-8406. doi: 10.1074/jbc.M111.300905  
49  
50 Talts, J. F., Andac, Z., Gohring, W., Brancaccio, A., & Timpl, R. (1999). Binding of the G  
51 domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides,  
52 alpha-dystroglycan and several extracellular matrix proteins. [Research Support, Non-  
53 U.S. Gov't]. *EMBO J*, 18(4), 863-870. doi: 10.1093/emboj/18.4.863  
54  
55  
56 Tisi, D., Talts, J. F., Timpl, R., & Hohenester, E. (2000). Structure of the C-terminal laminin  
57 G-like domain pair of the laminin alpha2 chain harbouring binding sites for alpha-  
58 dystroglycan and heparin. [Comparative Study  
59  
60

- 1  
2  
3 Research Support, Non-U.S. Gov't]. *EMBO J*, 19(7), 1432-1440. doi:  
4 10.1093/emboj/19.7.1432  
5  
6 Topaloglu, H., Brockington, M., Yuva, Y., Talim, B., Haliloglu, G., Blake, D., . . . Muntoni,  
7 F. (2003). FKRP gene mutations cause congenital muscular dystrophy, mental  
8 retardation, and cerebellar cysts. *Neurology*, 60(6), 988-992.  
9  
10 Torelli, S., Brown, S. C., Brockington, M., Dolatshad, N. F., Jimenez, C., Skordis, L., . . .  
11 Muntoni, F. (2005). Sub-cellular localisation of fukutin related protein in different cell  
12 lines and in the muscle of patients with MDC1C and LGMD2I. [Comparative Study  
13  
14 Research Support, Non-U.S. Gov't]. *Neuromuscul Disord*, 15(12), 836-843. doi:  
15 10.1016/j.nmd.2005.09.004  
16  
17 Tucker, J. D., Lu, P. J., Xiao, X., & Lu, Q. L. (2018). Overexpression of Mutant FKRP  
18 Restores Functional Glycosylation and Improves Dystrophic Phenotype in FKRP  
19 Mutant Mice. *Mol Ther Nucleic Acids*, 11, 216-227. doi: 10.1016/j.omtn.2018.02.008  
20  
21 von der Hagen, M., Kaindl, A. M., Koehler, K., Mitzscherling, P., Hausler, H. J., Stoltenburg-  
22 Didinger, G., & Huebner, A. (2006). Limb girdle muscular dystrophy type 2I caused  
23 by a novel missense mutation in the FKRP gene presenting as acute virus-associated  
24 myositis in infancy. *Eur J Pediatr*, 165(1), 62-63. doi: 10.1007/s00431-005-1752-6  
25  
26 Wahbi, K., Meune, C., Hamouda el, H., Stojkovic, T., Laforet, P., Becane, H. M., . . . Duboc,  
27 D. (2008). Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an  
28 echography, Holter ECG and magnetic resonance imaging study. *Neuromuscul*  
29 *Disord*, 18(8), 650-655. doi: 10.1016/j.nmd.2008.06.365  
30  
31 Walter, M. C., Petersen, J. A., Stucka, R., Fischer, D., Schroder, R., Vorgerd, M., . . .  
32 Lochmuller, H. (2004). FKRP (826C>A) frequently causes limb-girdle muscular  
33 dystrophy in German patients. *J Med Genet*, 41(4), e50.  
34  
35 Yamamoto, L. U., Velloso, F. J., Lima, B. L., Fogaca, L. L., de Paula, F., Vieira, N. M., . . .  
36 Vainzof, M. (2008). Muscle protein alterations in LGMD2I patients with different  
37 mutations in the Fukutin-related protein gene. *J Histochem Cytochem*, 56(11), 995-  
38 1001. doi: 10.1369/jhc.2008.951772  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure legends

**Figure 1. Cellular characterization of HAP1 WT and HAP1 FKRP-KO cell lines. (A)** Cellular morphology and endogenous FKRP cellular localization. Endogenous FKRP protein was detected in HAP1 WT cells (top panels), where the signal co-localized with the *cis*-Golgi Marker GM130 and the *trans*-Golgi marker TGN46, and was absent at these locations in HAP1 FKRP<sub>KO</sub> cells (bottom panels). Nuclei are labelled by DAPI staining. Scale bars: 30 $\mu$ m (bright-field), 10 $\mu$ m (fluorescence). **(B)** Small cytoplasmic volume and perturbed membrane morphology in HAP1 FKRP KO cells was observed compared to the HAP1 WT control cell line, based on the IF against membrane  $\beta$ -integrin and WGA. Image magnifications are presented in the right panels. Nuclei are labelled by DAPI staining. Scale bars: 20 $\mu$ m and 10 $\mu$ m for zooms **(C)** Characterization of  $\alpha$ -DG functional glycosylation in the two cell lines. The specific glycosylation, detected through the IIH6 antibody, was present in HAP1 WT but not in HAP1 FKRP KO as observed by confocal imaging. **(D)** Flow cytometry quantification of  $\alpha$ -DG functional glycosylation of HAP1-WT and HAP1 FKRP KO labelled with secondary antibody alone (II) or in combination with IIH6 primary antibody against  $\alpha$ -DG functional glycosylation (I + II). \*\*\*\*p  $\leq$  0.0001.

**Figure 2. Cellular localization and functional characterization of FKRP mutant proteins in HAP1 FKRP KO cells. (A)** FKRPmCh mutant proteins cellular localization after IF for the *trans*-Golgi compartment (TGN46). Nuclei are labelled by DAPI staining. Scale bar: 5 $\mu$ m. **(B)** Functional characterization of FKRP mutant proteins through detection of  $\alpha$ -DG functional glycosylation after lentivirus transduction in HAP1 FKRP KO cells. In this condition, the low copy number achieved allows observation along time. The levels of the specific  $\alpha$ -DG glycosylation, as well as the levels of mCherry signal as a measure of

FKRPMCh protein production, were followed and quantified through time. The levels of glycosylation were assessed only for the mCherry positive population representing the successfully transfected cells. Data is presented as the integrated Mean Fluorescence Intensity (iMFI = MFI \* % positive cells) values in arbitrary units (A.U.) within this mCherry population.

**Figure 3. Cellular localization and functional characterization of FKRPs with missense mutations localized between residue 300 and 328.** (A) FKRPMCh mutant proteins cellular localization by IF for the *trans*-Golgi compartment (TGN46) after transfection in HAP1 FKRPs KO cells. The mCherry signal of the fusion proteins specifically co-localized with the *trans*-Golgi for FKRPs WT and all the mutants within residue 300 and 321. Mutant Y328S displayed a *trans*-Golgi co-localization as well as a cytoplasmic signal corresponding to the ER. Nuclei are labelled by DAPI staining. Scale bar: 5µm. (B) Functional characterization of FKRPs mutant proteins through detection of α-DG functional glycosylation after transfection in HAP1 FKRPs KO cells. The levels of glycosylation were assessed only for the mCherry positive population representing the successfully transfected cells. The functional level of the catalytically dead NNN mutant protein is represented as a dashed line. Data is presented as relative iMFI (MFI \* % positive cells) values in arbitrary units (A.U.). ns= non-significant, \*p ≤ 0.05, \*\*p ≤ 0.01, \*\*\*p ≤ 0.001, \*\*\*\*p ≤ 0.0001.

**Figure 4. Graphic model depicting proposed steps and final outcomes of normal and abnormal FKRPs protein folding/function in physiological conditions *in vivo*.** (A) Normal physiological condition. 1) FKRPs is correctly folded in the ER; 2) FKRPs is trafficked to the *trans*-Golgi; 3) FKRPs transfers Rbo-5P to α-DG glycosylation chain; 4) α-DG is functionally glycosylated at the membrane; 5) Correct ECM binding ensures sarcolemma integrity. (B) Patient with missense mutation in FKRPs- protein is retained in the ER. 1) Mutation in FKRPs

1  
2  
3 lead to ER-retained misfolded protein; 2) FKRP protein is not able to traffic correctly to the  
4 Golgi; 3) The  $\alpha$ -DG glycosylation chain is not extended; 4) Defects in ECM binding lead to  
5 membrane fragility and muscle dystrophy. (C) Patient with missense mutation in FKRP-  
6 protein is not functionally active. 1) FKRP is correctly folded in the ER; 2) FKRP is  
7 trafficked to the *trans*-Golgi; 3) FKRP does not achieve functional conformation in the Golgi  
8 and fails to transfers Rbo-5P to  $\alpha$ -DG glycosylation chain; 4) The  $\alpha$ -DG glycosylation chain is  
9 not extended; 5) Defects in ECM binding lead to membrane fragility and muscle dystrophy.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

**Table 1. Description of the studied FKRP patient variants.** The information presented includes the associated pathology, number of case reports and the corresponding references (Leiden Muscular Dystrophy pages; [www.dmd.nl/](http://www.dmd.nl/)). **(A)** FKRP missense mutants used in the subcellular localization and functional studies. **(B)** FKRP missense mutations localized between protein residues 300 and 328. The human *FKRP* gene (Gene ID: 79147, NM\_001039885.2, CCDS12691.1) is used and gene variants are described using HGVS-nomenclature (<http://varnomen.hgvs.org>). CMD = Congenital Muscular Dystrophy, MEB = Muscle-Eye-Brain disease, WWS = Walker-Warburg Syndrome, LIS = Lissencephaly, LGMD2I = Limb-Girdle Muscular Dystrophy type 2I.

**A.**

Human genetic variants	Pathology†	# Reports†	References
NM_001039885.2:c.545A>G NM_001039885.2:p.Tyr182Cys (Y182C)	LGMD2I	6	(de Paula et al., 2003; Wahbi et al., 2008; Yamamoto et al., 2008)
NM_001039885.2:c.663C>A NM_001039885.2:p.Ser221Arg (S221R)	CMD	2	(Mercuri et al., 2006; Topaloglu et al., 2003)
NM_001039885.2:c.826C>A NM_001039885.2:p.Leu276Ile (L276I)	LGMD2I	240	Several reports
NM_001039885.2:c.899T>C NM_001039885.2:p.Val300Ala (V300A)	LGMD2I	5	(de Paula et al., 2003; Walter et al., 2004; Yamamoto et al., 2008)
NM_001039885.2:c.1213G>T NM_001039885.2:p.Val405Leu (V405L)	CMD	1	(Louhichi et al., 2004)
NM_001039885.2:c.1343C>T NM_001039885.2:p.Pro448Leu (P448L)	CMD	3	(Brockington et al., 2001; Dolatshad et al., 2005; Mercuri et al., 2003)
NM_001039885.2:c.1364C>A NM_001039885.2:p.Ala455Asp (A455D)	LGMD2I/CMD	14	(Louhichi et al., 2004) (Kefi, Amouri, Chabrak, Mechmeche, & Hentati, 2008;
†Leiden Muscular Dystrophy pages			

## B.

Human genetic variants	Pathology†	# Reports†	References
NM_001039885.2:c.914C>T NM_001039885.2:p.Pro305Leu (P305L)	LGMD2I	2	-
NM_001039885.2:c.919T>A NM_001039885.2:p.Tyr307Asn (Y307N)	MEB/CMD	10	(Beltran-Valero de Bernabe, 2004) (Mercuri et al., 2006; Torelli et al., 2005) (Wahbi et
NM_001039885.2:c.926A>G NM_001039885.2:p.Tyr309Cys (Y309C)	-	1	(Brockington et al., 2001; Mercuri et al., 2003; Torelli et al., 2005)
NM_001039885.2:c.934C>T NM_001039885.2:p.Arg312Cys (R312C)	-	1	(Brockington et al., 2001)
NM_001039885.2:c.941C>T NM_001039885.2:p.Thr314Met (T314M)	CMD/LGMD2I	6	-
NM_001039885.2:c.940A>C NM_001039885.2:p.Thr314Pro (T314P)	LIS	2	(Bouchet et al., 2007)
NM_001039885.2:c.946C>A NM_001039885.2:p.Pro316Thr (P316T)	CMD/LGMD2I	4	(Mercuri et al., 2006; Topaloglu et al., 2003)
NM_001039885.2:c.946C>T NM_001039885.2:p.Pro316Ser (P316S)	-	1	(Mercuri et al., 2003)
NM_001039885.2:c.947C>G NM_001039885.2:p.Pro316Arg (P316R)	CMD/LGMD2I	3	(Brockington et al., 2001; Quijano-Roy et al., 2006)
NM_001039885.2:c.953G>A NM_001039885.2:p.Cys318Tyr (C318Y)	WWS	2	(Beltran-Valero de Bernabe, 2004) (Mercuri et al., 2006)
NM_001039885.2:c.956T>G NM_001039885.2:p.Leu319Arg (L319R)	LGMD2I	1	(Guglieri, Straub, Bushby, & Lochmuller, 2008)
NM_001039885.2:c.962C>A NM_001039885.2:p.Ala321Glu (A321E)	LGMD2I	1	(von der Hagen et al., 2006)
NM_001039885.2:c.983A>C NM_001039885.2:p.Tyr328Ser (Y328S)	CMD/LGMD2I	2	(Brockington et al., 2001; Quijano-Roy et al., 2006; Wahbi et al., 2008)
†Leiden Muscular Dystrophy pages			

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





Figure 1

210x297mm (300 x 300 DPI)

A



B





Figure 2

210x297mm (300 x 300 DPI)

A



B




Figure 3

210x297mm (300 x 300 DPI)





Figure 4


210x297mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


A



B




C




Supp. Figure 1. Characterization of the FKRPmCh fusion protein.

1  
2  
3 (A) Correct co-localization of the mCherry signal in the FKRPmCh protein and FKRP  
4 labelling confirms the integrity of the fusion protein. Nuclei are labelled by DAPI staining.  
5  
6 Scale bar: 5 $\mu$ m. (B) Co-localization of the mCherry signal in the FKRPmCh protein with the  
7  
8 *cis*- (GM130) and *trans*-Golgi (TGN46) labelling confirming that the addition of the mCherry  
9  
10 fluorescent reporter did not interfere with the normal FKRP protein traffic. Pearson  
11  
12 correlation coefficients between the red (mCh) and green (GM130/TGN46) calculated using  
13  
14 the JACoP plugin for ImageJ are presented for the magnified images. Nuclei are labelled by  
15  
16 DAPI staining. Scale bar: 10 $\mu$ m. (C) Confocal imaging after labelling of  $\alpha$ -DG functional  
17  
18 glycosylation (IIH6) in non-permeabilized conditions and transfection of FKRPmCh-WT in  
19  
20 HAP1 FKRP KO cells. Nuclei are labelled by DAPI staining. Scale bar: 10 $\mu$ m.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Supp. Figure 2. ER-retention of FKRP mutant proteins.**


FKRPMCh WT and V405L mutant protein cellular localization after IF staining for the ER compartment (CNX). The mCherry signal of the fusion proteins specifically co-localized with the ER for FKRP V405L, as an example, confirming that the cytoplasmic signals observed represents ER-retained mutant proteins. Nuclei are labelled by DAPI staining. Scale bar: 10 $\mu$ m.



Supp. Figure 3. Flow cytometry data and gates in HAP1-WT and HAP1 FKRP KO cells.

1  
2  
3 Flow cytometry data of HAP1-WT, HAP1 FKRP KO and HAP1 FKRP KO cells transfected  
4 with FKRPmCh WT construct labelled with A488 secondary antibody alone (II) or in  
5 combination with IIH6 primary antibody against  $\alpha$ -DG functional glycosylation (I + II). Cell  
6 gates were defined using the appropriate experimental controls. mCherry (mCh) and A488  
7 signal intensities are shown in axis. The data shows that the intensity of labelling (A488) of  
8 the FKRPmCh WT transfected HAP1 FKRP KO cells are in the range of the levels of  
9 intensity seen in the HAP1 WT cells (HAP1 WT I+II).  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review



**Supp. Figure 4. Function of FKR mutant proteins at 45h of expression.**

Functional characterization of FKR mutant proteins through detection of  $\alpha$ -DG functional glycosylation. Only functional levels at 45h are depicted confirming that the mutant proteins, E2E5, V300A and V405L, display levels comparable to the catalytically dead NNN mutant protein. The levels of glycosylation were assessed only for the mCherry positive population representing the successfully transfected cells. Data is presented as relative iMFI (MFI \* % positive cells) values in arbitrary units (A.U.). ns= non-significant, \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ .

Variant	PolyPhen-2	PROVEAN		MutationAssessor	
	Prediction	Prediction	Score	Func. Impact	FI score
Y182C	Benign	Deleterious	-4.767	Low	1.385
S221R	Probably damaging	Neutral	-2.367	Low	1.445
L276I	Possibly damaging	Neutral	-0.849	Low	1.355
V300A	Possibly damaging	Deleterious	-3.219	Low	1.87
V405L	Probably damaging	Neutral	-2.372	Medium	2.35
P448L	Probably damaging	Deleterious	-8.165	Medium	2.465
A455D	Probably damaging	Deleterious	-3.969	Medium	2.005
P305L	Probably damaging	Deleterious	-8.796	Medium	2.02
Y307N	Probably damaging	Deleterious	-7.733	Medium	2.02
Y309C	Probably damaging	Deleterious	-6.507	Low	1.87
R312C	Probably damaging	Deleterious	-5.987	Low	1.73
T314M	Probably damaging	Deleterious	-4.744	Medium	2.455
T314P	Probably damaging	Deleterious	-5.211	Medium	3.005
P316T	Probably damaging	Deleterious	-6.404	Medium	3.035
P316S	Probably damaging	Deleterious	-6.404	Medium	3.035
P316R	Probably damaging	Deleterious	-7.533	Medium	2.69
C318Y	Probably damaging	Deleterious	-9.426	Medium	3.14
L319R	Probably damaging	Deleterious	-4.198	Medium	2.51
A321E	Probably damaging	Neutral	-1.115	Low	1.91
Y328S	Possibly damaging	Deleterious	-3.526	Low	1.925

**Supp. Table 1. Prediction scores of deleteriousness for FKR protein variants.** The prediction scores of three independent online predictors (PolyPhen-2, PROVEAN and MutationAssessor) are presented for the human FKR protein with the introduced specific variants.

1  
2  
3  
4 Functional and cellular localization diversity associated with  
5  
6  
7  
8 Fukutin related protein patient genetic variants  
9  
10

11 Sara F. Henriques<sup>1</sup>, Evelyne Gicquel<sup>1</sup>, Justine Marsolier<sup>1</sup> and Isabelle Richard<sup>1</sup>

12  
13  
14  
15 1 INTEGRARE Research Unit, UMR951, Généthon, INSERM, Université Evry Val  
16  
17 d'Essonne, Université Paris-Saclay, 91002, Evry, France  
18  
19

20  
21  
22  
23  
24 **Funding information**  
25

26  
27 Généthon is part of the Biotherapies Institute for Rare Diseases (BIRD) which is supported by  
28  
29 the Association Française contre les Myopathies (AFM-Téléthon). SH was supported by a  
30  
31 PhD fellowship from the University of Paris-Saclay.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Genetic variants in Fukutin related protein (FKRP), an essential enzyme of the glycosylation pathway of  $\alpha$ -dystroglycan, can lead to pathologies with different severities affecting the eye, brain and muscle tissues. Here, we generate an *in vitro* cellular system to characterize the cellular localization as well as the functional potential of the most common *FKRP* patient missense mutations. We observe a differential retention in the Endoplasmic Reticulum (ER), indication of misfolded proteins. We find data supporting ~~determine~~ that mutant proteins able to overcome this ER-retention through overexpression present functional levels comparable to the wild-type. We also identify a specific region in FKRP protein localized between residues 300 and 321 in which genetic variants found in patients lead to correctly localized proteins but which are nevertheless functionally impaired or catalytically dead in our model, indicating that this particular region is-might be important for the enzymatic activity of FKRP within the Golgi. Our system thus allows the functional testing of patient specific mutant proteins and the identification of candidate mutants to be further explored with the aim of finding pharmacological treatments targeting the protein quality control system.

## Keywords

FKRP; LGMD2I; dystroglycan; genetic variants; missense mutations; protein quality control; glycosylation.

## 1. Introduction

Muscular dystrophies are a group of monogenic diseases affecting the skeletal muscle and characterized by a progressive loss of the muscle mass. One substantial group of muscle dystrophies termed “dystroglycanopathies” encompasses different genetic pathologies, ultimately characterized by hypoglycosylation of the protein  $\alpha$ -dystroglycan ( $\alpha$ -DG). This protein is a fundamental component of the dystrophin-associated glycoprotein complex (DGC) in the muscles and also plays additional important roles in other tissues such as the eye and brain. Through a complex and specific glycosylation of the protein, raising its weight from 70 to 156 kDa in muscle (Barresi & Campbell, 2006), the plasma membrane is anchored to different extracellular-matrix (ECM) components (Hohenester, Tisi, Talts, & Timpl, 1999; Talts, Andac, Gohring, Brancaccio, & Timpl, 1999; Tisi, Talts, Timpl, & Hohenester, 2000), such as laminin in the cardiac and skeletal muscles (Ervasti & Campbell, 1993). The connexion of the fibers to the ECM is crucial for membrane stabilization, especially during muscle contraction/relaxation cycles. In dystroglycanopathies, hypoglycosylation of  $\alpha$ -DG leads to disruption of plasma membrane attachment, to fragility of the tissue and therefore to a dystrophic process.

The genetic basis of dystroglycanopathies is very heterogeneous, reflecting the peculiar machinery of enzymes contributing to the glycosylation of  $\alpha$ -DG. At present, genetic variants in 17 different genes coding for enzymes of the  $\alpha$ -DG glycosylation pathway have been identified as being implicated in these disorders, which range from the severe Walker-Warburg Syndrome (WWS), Muscle-Eye-Brain disease (MEB) or Congenital Muscular Dystrophy (CMD) to the mildest Limb-Girdle Muscular Dystrophies (LGMDs).

1  
2  
3 Genetic variants in the gene coding for Fukutin-related protein (*FKRP*) (FKRP; MIM#  
4 606596), one of the enzymes of the  $\alpha$ -DG glycosylation pathway, can lead to all the  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Genetic variants in the gene coding for Fukutin-related protein (*FKRP*) (FKRP; MIM# 606596), one of the enzymes of the  $\alpha$ -DG glycosylation pathway, can lead to all the aforementioned pathologies (MIM# 613153, 606612, 607155) (Beltran-Valero de Bernabe, 2004; Brockington et al., 2001; Richard, Laurent, Cirak, & Vissing, 2016). FKRP protein is a type II transmembrane protein localized in the *mid/trans*-Golgi apparatus of the skeletal muscle cells (Alhamidi et al., 2011). It is characterized by a short cytoplasmic domain followed by transmembrane, stem and catalytic domains, the last one possessing a DxD amino-acid motif critical for the catalytic function of the protein (Esapa et al., 2002). FKRP was described as a transferase of ribitol-phosphate into the growing glycosylation chain using as substrate the precursor molecule CDP-ribitol, and acting in succession to another related enzyme of the pathway, Fukutin (*FKTN*) (FKTN; MIM# 607440) (Gerin et al., 2016; Kanagawa et al., 2016). Of note, FKRP and FKTN were recently shown to act also as a CDP-glycerol transferases, which inhibits the functional glycosylation of  $\alpha$ -DG (Imae et al., 2018).

The most common types of *FKRP* patient genetic variants are missense mutations, with, in particular, a high prevalence of a specific genetic variant, the [NM\\_001039885.2:p.Leu276Ile \(L276I\)](#) (Richard et al., 2016). Missense mutations, resulting in an amino-acid change, can lead to protein folding defects when the amino-acid properties are not preserved. These misfolded proteins can be detected and blocked by the quality control (QC) system of the cells and, specifically in the case of transmembrane and secretory proteins, be retained in the Endoplasmic reticulum (ER) and directed to premature degradation by the proteasome through the ER-associated degradation (ERAD) system. Interestingly, despite the presence of the genetic variant, a certain degree of biological activity of the protein can still be preserved, suggesting that “rescue” of these proteins from the strict QC surveillance and degradation systems could ameliorate the related pathology. Indeed, pharmacological treatments proved

1  
2  
3 successful *in vitro* for the rescue of FKTN (Tachikawa, Kanagawa, Yu, Kobayashi, & Toda,  
4 2012) or of other mutated proteins of the DGC such as the sarcoglycans (Carotti et al., 2018;  
5 Soheili et al., 2012). Some of the most prevalent *FKRP* missense mutations have been  
6 described to be retained in the ER (Esapa et al., 2002; Esapa, McIlhinney, & Blake, 2005;  
7 Keramaris-Vrantsis et al., 2007; Matsumoto et al., 2004; Torelli et al., 2005), leading to loss  
8 of function though cellular mislocalization from the Golgi, the cellular compartment where  
9 *FKRP* exerts its function. The functional potential of these ER-retained mutant proteins if  
10 properly rescued to the Golgi has not been assessed, a crucial characteristic to determine at  
11 the time when pharmacological treatments aiming to target the ERQC and ERAD systems are  
12 envisaged for patients. Beside these cases, other *FKRP* genetic variants were shown to be  
13 correctly localized in the Golgi compartment, some of which being implicated in severe  
14 phenotypes such as WWS (Keramaris-Vrantsis et al., 2007). The underlying explanation of  
15 the discrepancies between the correct localization and the severity of the phenotype has not  
16 been elucidated.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36 In this study, we addressed the current gap in knowledge about the functional potential of  
37 mutant proteins bearing some of the most common *FKRP* patient genetic variants. We  
38 developed heterologous models, which permitted the investigation of the subcellular  
39 localization and functional status of the disease-causing *FKRP* mutated proteins. We  
40 demonstrated that genetic variants ~~that are~~observed to be retained in the ER can nevertheless  
41 be able to overcome this retention and present activity levels comparable to wild-type ~~activity~~.  
42  
43  
44  
45  
46  
47  
48  
49  
50 In addition, we observed that some of the *FKRP* mutant proteins that correctly localize in the  
51 Golgi present either no or severely impaired function, indicating that the pathological  
52 mechanism of these *FKRP* genetic variants might corresponds to a direct perturbation of the  
53 enzymatic function whereas the mutated protein is considered normal by the QC. Taken  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 together, this data ~~has~~ can bring important implications for the development of therapeutic  
4 strategies in FKRP deficiencies for which there is still no curative treatment, more specifically  
5  
6 for patients affected by genetic variants leading to ER-retained but nonetheless functional  
7  
8 proteins.  
9  
10  
11  
12  
13  
14  
15  
16

## 17 **2. Materials and methods**

18  
19  
20 **2.1 Cloning and mutagenesis.** The FKRP fusion protein comprising the human *FKRP* CCDS  
21 (Gene ID: 79147, NM\_001039885.2, CCDS12691.1), the prototypical FLAG sequence  
22 (DYKDDDDK), a flexible type linker (3xGGGGS) (Chen, Zaro, & Shen, 2013) and a  
23 mCherry fluorescent reporter sequence was synthesized and codon-optimized for human  
24 expression by GENEWIZ. The transgene was inserted into a lentivirus backbone plasmid  
25 under the transcriptional control of the CMV promoter. The final construct was named  
26 FKRPmCh. Mutagenesis was performed in FKRPmCh plasmid using the QuickChange XL  
27 Mutagenesis Kit (Agilent) according to the supplier's protocol with the mutant constructs  
28 differing from the wild-type only by the modification of the codon of the genetic variant.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 **2.2 Cell culture.** Near-haploid human HAP1 cells are commercialized by Horizon  
43 Discovery™. The HAP1 FKRP<sub>KO</sub> cell line, bearing a 17 base-pair (bp) deletion in the  
44 endogenous *FKRP* gene, was available off-the-shelf (Product ID: HZGHC000726c009). The  
45 cells were grown in Iscove's Modified Dulbecco's Medium (IMDM) (Thermo Fisher  
46 Scientific) with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific) and 10 µg/ml of  
47 Gentamicin (Thermo Fisher Scientific) and incubated at 37°C and atmospheric humidity of  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
5% CO<sub>2</sub>. Cells were mycoplasma negative.

1  
2  
3 **2.3 Transfections and transductions.** Cells were seeded in six or twelve well-plates at 60%  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**2.3 Transfections and transductions.** Cells were seeded in six or twelve well-plates at 60% confluence. Cells used for immuno-fluorescence (IF) staining were seeded on glass coverslips in the bottom of the well. Transfection of FKRPmCh plasmids were conducted using Turbofectin 8.0 reagent (Origene) for 48h accordingly to the supplier's protocol and a Turbofectin/DNA ratio of 3: 1 with the same DNA concentrations. Transduction of lentiviral particles expressing FKRPmCh WT or mutant constructs were performed at multiplicity of infection (MOI) of three and in combination with Polybrene (6ug/mL; Sigma-Aldrich). Incubation with the viral particles was performed for 18h at 37°C and 5% CO<sub>2</sub>, after which the medium was replaced and the cells were kept at 37°C until further analysis.

**2.4 Immuno-fluorescence confocal staining, acquisition and analysis.** The IF staining for confocal microscopy was performed as follows: the cells were fixed in formaldehyde 3.7% (Sigma-Aldrich) for 15 minutes at room temperature. If permeabilization was required, Triton X-100 0.5% (Sigma-Aldrich) was used for 5 min at room temperature. Saturation was performed in PBS 20% foetal bovine serum (FBS) for 1h at room temperature. The primary antibodies Calnexin (Rabbit, ab22595, Abcam), GM130 (Mouse, 610822, BD-Biosciences), TGN46 (Sheep, AHP500GT, BioRad),  $\alpha$ -dystroglycan (IIH6; Mouse, sc-53987, Santa Cruz Biotechnology),  $\beta$ -integrin (Mouse, sc-13590, Santa Cruz Biotechnology) or Wheat Germ Agglutinin (WGA-Alexa Fluor™ 488 Conjugate, W11261, Thermo Fisher Scientific) were added in the appropriate dilutions in PBS 2% FBS for 3h at room-temperature or over-night at 4°C. After three washes with PBS for 5 minutes, incubation with secondary antibodies Alexa Fluor™-488 and Alexa Fluor™-594 fluorescent-conjugated antibodies (Thermo Fisher Scientific) was performed in PBS 2% FBS for 1h at room-temperature in the dark. Three washes with PBS for 5 minutes were performed and the glass slides were mounted in DAPI Fluoromount-G® (CliniSciences) overnight at 4°C. For the endogenous FKRP protein

1  
2  
3 labelling, the fluorescent signal amplification Tyramide SuperBoost Kit (Anti-rabbit Alexa  
4 Fluor™-488, B40922, Thermo Fisher Scientific) was used accordingly to the supplier's  
5 protocol. Confocal images were taken using the Leica SP8 confocal microscope (Leica) at  
6  
7 either the 40X, 63X or 100X oil-objectives. Bright-field images were taken using the Evos  
8 microscope (Thermo Fisher Scientific) at a 40X objective. Images were treated and analysed  
9  
10 using ImageJ/Fiji software (Schindelin et al., 2012) and the Pearson's coefficients of  
11 correlation were calculated using the JACoP plugin (Bolte & Cordelieres, 2006).  
12  
13  
14  
15  
16  
17  
18  
19

20 **2.5 Flow cytometry staining, acquisition and analysis.** The staining for flow cytometry was  
21 performed as follows: saturation was performed in cold PBS 2% FBS + human FcR blocking  
22 agent (Miltenyi Biotec) for 20 minutes at 4°C. The primary antibody  $\alpha$ -dystroglycan (IIH6;  
23 Mouse, sc-53987, Santa Cruz Biotechnology) was diluted at a ratio 1/20 in cold PBS 2% FBS  
24 and incubated for 20 minutes at 4°C. After one wash with cold PBS, incubation with the Goat  
25 anti-Mouse Alexa Fluor™-488 fluorescent-conjugated secondary antibody (Thermo Fisher  
26 Scientific) was performed in PBS 2% FBS for 20 minutes at 4°C in the dark. Three washes  
27 with cold PBS were performed and the final cell pellets were resuspended in cold PBS 2%  
28 FBS and kept in ice until further analysis. Positive (HAP1-WT) and negative (secondary  
29 antibody alone on HAP1- FKRP<sub>KO</sub>) controls were included in all experiments.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 The CytoFLEX flow cytometer (Beckman Coulter) and the B525/40 BP (A488) and Y610/20  
45 BP (mCherry) lasers were used with the same settings for all experiments. Flow cytometry  
46 data was treated and analysed using the Kaluza analysis software (Beckman Coulter). Flow  
47 cytometry values are presented as the integrated Mean Fluorescence Intensity (iMFI). iMFI is  
48 calculated as the MFI multiplied by the percentage of positive cells for the glycosylation  
49 (IIH6) signal within the mCherry positive cell population which equals correctly transfected  
50 cells. The iMFI  $\alpha$ -DG glycosylation values of patient fibroblasts by flow cytometry were  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 shown to be closely related to the glycosylation levels in the corresponding muscle biopsies  
4  
5 (Stevens et al., 2013). Flow cytometry values were normalized against the transduced FKRP  
6  
7 WT construct in each independent experiment.  
8  
9

10  
11 **2.6 Prediction of functional impact of FKRP variants.** The online predictor tools  
12  
13 Polymorphism Phenotyping v2 (PolyPhen-2 (Adzhubei et al., 2010),  
14  
15 <http://genetics.bwh.harvard.edu/pph2/>), Protein Variation Effect Analyzer (PROVEAN (Choi,  
16  
17 Sims, Murphy, Miller, & Chan, 2012), [http://provean.jcvi.org/seq\\_submit.php](http://provean.jcvi.org/seq_submit.php)) and  
18  
19 MutationAssessor release 3 ((Reva, Antipin, & Sander, 2011), <http://mutationassessor.org/r3/>)  
20  
21 were used at the last current version (March 2019) and run with the default settings.  
22  
23  
24  
25

26  
27 **2.7 Data and statistical analysis.** The GraphPad PRISM 7.01 program (GraphPad Software  
28  
29 Inc.) was used for calculating statistics using unpaired t-test. The results represent the average  
30  
31  $\pm$  SEM of at least three independent experiments (cell culture, transfection/transduction and  
32  
33 analysis performed in different days). P-values were calculated using the WT as control and P  
34  
35  $<0.05$ . Regression curves were calculated using a centred second order polynomial (quadratic)  
36  
37 equation with ordinary fit parameters. ns= non-significant, \*p  $\leq 0.05$ , \*\*p  $\leq 0.01$ , \*\*\*p  $\leq 0.001$ ,  
38  
39 \*\*\*\*p  $\leq 0.0001$ .  
40  
41  
42  
43  
44  
45  
46

## 47 **3. Results**

### 48 **3.1 Cellular model validation**

49  
50  
51  
52  
53  
54 In order to study the cellular consequences of *FKRP* patient genetic variants *in vitro*, we took  
55  
56 advantage of the near-haploid HAP1 cell line as these cells were previously shown to support  
57  
58  
59  
60

1  
2  
3 the complete  $\alpha$ -DG chain of glycosylation (Endo et al., 2015; Riemersma et al., 2015). To  
4 avoid interference by the endogenous FKR<sub>P</sub> protein, a CRISPR/Cas9-induced FKR<sub>P</sub> knock-  
5 out (KO) cell line was used (HAP1-FKR<sub>P</sub><sub>KO</sub>). Validation of the cellular model was performed  
6 by FKR<sub>P</sub> immuno-labelling and  $\alpha$ -DG glycosylation staining. Using an immuno-fluorescence  
7 (IF) amplification system, we demonstrated the absence of endogenous FKR<sub>P</sub> protein in the  
8 HAP1-FKR<sub>P</sub><sub>KO</sub> cells whereas the signal co-localized with the Golgi markers (GM130 and  
9 TGN46 for *cis*- and *trans*-Golgi respectively) in the HAP1-WT cell line as expected (Figure  
10 1A). The HAP1-FKR<sub>P</sub><sub>KO</sub> cell line, while presenting normal cell growth, was characterized by  
11 small cytoplasmic volume and membrane disturbances, specifically deficiency in filipodia, as  
12 detected by membrane staining for  $\beta$ -integrin and Wheat Germ Agglutinin (WGA) (Figure  
13 1B). IF and flow-cytometry analysis showed a substantial reduction of the functional  $\alpha$ -DG  
14 glycosylation at the cell membrane based on the IIH6 specific antibody (Figure 1C),  
15 confirming the absence of FKR<sub>P</sub> activity in HAP1-FKR<sub>P</sub><sub>KO</sub> cells and the utility of using this  
16 cell line for FKR<sub>P</sub> mutant protein characterization.

17  
18  
19 To be able to select the exogenous FKR<sub>P</sub> positive cells in flow cytometry experiments and to  
20 directly detect the protein in cellular localization experiments without the need of antibodies,  
21 we generated a fluorescently labelled fusion protein. This protein consists of the human *FKRP*  
22 coding sequence fused, at its C-terminus and through a flexible linker, to a mCherry (mCh)  
23 fluorescent reporter protein (FKR<sub>P</sub>mCh). IF staining experiments demonstrated the integrity  
24 of the fusion protein since the mCherry signal co-localized with the labelling for FKR<sub>P</sub> and  
25 with the *trans*-Golgi marker TGN46 (Supp. Figures S1A and S1B). In addition, only the  
26 mCherry positive cells were positive for membrane staining with the IIH6 antibody in non-  
27 permeabilized conditions (Supp. Figure S1C), indicating that the addition of the fluorescent  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 reporter did not alter the normal cellular localization and function of the WT FKRP protein  
4  
5 and that the construct could be used further for genetic variants characterization.  
6  
7

### 8 **3.2 Cellular localization of FKRP mutant proteins**

9  
10  
11 With the aim of characterizing FKRP mutant proteins using our overexpression system, we  
12  
13 chose to test seven missense patient genetic variants associated with pathologies ranging from  
14  
15 the severe CMD to the mild LGMD2I and localized throughout the entire length of the protein  
16  
17 (Table 1A). In addition to the patient genetic variants, two control mutants were used. In the  
18  
19 first, the di-Arginine (R) motif at positions 2 and 5 (R2R5) responsible for the Golgi  
20  
21 positioning was mutated to Glutamic acid (E) residues (E2E5). In the second, the catalytic  
22  
23 residues composed of two Aspartic acids (D) and a Valine (V) in positions 362-364 (DvD)  
24  
25 were mutated into asparagine residues (N) (NNN). The first mutant protein was previously  
26  
27 described as being unable to traffic from the ER to the Golgi, whereas the second was shown  
28  
29 to abrogate the enzymatic activity of FKRP (Esapa et al., 2002).  
30  
31  
32  
33  
34  
35

36 When overexpressed in HAP1-FKRP<sub>KO</sub> cells, the different constructs presented three different  
37  
38 profiles. The WT construct co-localized with the *trans*-Golgi, as well as the L276I,  
39  
40 [NM\\_001039885.2:p.Tyr182Cys \(Y182C\)](#) and [NM\\_001039885.2:p.Val300Ala \(V300A\)](#)  
41  
42 mutant proteins (Figure 2A). The mCherry signal of the E2E5 and  
43  
44 [NM\\_001039885.2:p.Val405Leu \(V405L\)](#) mutants presented a cytoplasmic localization, later  
45  
46 confirmed to co-localize with the ER marker calnexin (CNX) (Supp. Figure S2). Finally, we  
47  
48 observed a dual ER/Golgi co-localization for the NNN, [NM\\_001039885.2:p.Ser221Arg](#)  
49  
50 [\(S221R\)](#), [NM\\_001039885.2:p.Pro448Leu \(P448L\)](#) and [NM\\_001039885.2:p.Ala455Asp](#)  
51  
52 [\(A455D\)](#) mutant proteins, indicating that these proteins were retained in the ER but were  
53  
54 nevertheless able to overcome this retention. Overall, we concluded that, in our system, some  
55  
56  
57  
58  
59  
60

1  
2  
3 genetic variants lead to different levels of ER-retention but that evasion from this system is  
4  
5 possible for a number of these mutant proteins.  
6  
7

### 8 **3.3 Functional analysis of FKRP mutant proteins**

9  
10  
11 Given that some mutants were co-localized in the Golgi, we tested their protein level and  
12  
13 potential for functionality by flow-cytometry using the mCherry and glycosylation signals,  
14  
15 respectively (Supp. Figure S3). We observed that the amount of FKRPmCh protein steadily  
16  
17 increased as in the WT for all mutants with the exception of the E2E5, V405L and A455D  
18  
19 mutants, suggesting that the presence of the genetic variant may leads to protein instability  
20  
21 (Figure 2B). As expected, the increase of FKRPmCh amount was associated with an increase  
22  
23 in  $\alpha$ -DG functional glycosylation for the WT in the mCherry positive population. The Y182C  
24  
25 and L276I mutants led to the same glycosylation levels than the WT, demonstrating a fully  
26  
27 functional capacity, whereas the S221R, P448L and A455D, although displaying a slower  
28  
29 increase, soon caught up with WT functional levels at 45h (Supp. Figure S4). The reduced  
30  
31 level of glycosylation observed for the V405L is probably related to the low level of the  
32  
33 protein. The NNN mutant control was functionally fully impaired as predicted since  
34  
35 corresponding to a catalytically dead enzyme while the E2E5 mutant displayed a marked  
36  
37 functional reduction most likely due to the impaired traffic to the Golgi compartment as  
38  
39 demonstrated in the IF staining. Remarkably, the V300A mutant protein, which was correctly  
40  
41 localized in the Golgi apparatus, displayed a striking reduced level of glycosylation,  
42  
43 indicating that, although the protein is able to traffic correctly, it fails to extend the  $\alpha$ -DG  
44  
45 glycosylation moiety. Taken together, our results showed that overexpression of FKRP  
46  
47 mutant proteins in the HAP1-FKRP<sub>KO</sub> cell line can be used to study the localization and the  
48  
49 function potential of FKRP mutant proteins. Additionally, we showed that characterization of  
50  
51 cellular localization alone is not sufficient to infer protein function.  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 3.4 Characterization of *FKRP* patient genetic variants localized between residues 300 and 328

We were intrigued about the functional impairment induced by V300A, which is located at the beginning of the predicted catalytic domain (Alhamidi et al., 2011). The corresponding mutant protein did not present signs of ER-retention nor was its protein level low by flow cytometry, indicating that the protein was not identified by the QC/ERAD systems as misfolded. Yet, this protein was not able to function properly, i.e. glycosylation of  $\alpha$ -DG, despite the mutated residue not being localized in the DvD catalytic core residues (positions 362-364). We decided to investigate further the cellular localization and function of other genetic variants positioned downstream of the 300 Valine residue and in the beginning of the catalytic domain based on the published *FKRP* model (Alhamidi et al., 2011). For this purpose, we generated 14 additional patient genetic variants present between residues 300 and 328 of the *FKRP* protein (Table 1B). Our mutant panel included [NM\\_001039885.2:p.Tyr307Asn \(Y307N\)](#) and [NM\\_001039885.2:p.Cys318Tyr \(C318Y\)](#), previously characterized to be localized in the Golgi in other cell types (Dolatshad et al., 2005; Torelli et al., 2005). The associated phenotypes encompassed all severities, with the majority of genetic variants being reported in the Leiden Muscular Dystrophy database only one or two times.

The IF staining demonstrated that, alike the V300A mutant, all these additional *FKRP* mutant proteins, to the exception of the [NM\\_001039885.2:p.Tyr328Ser \(Y328S\)](#), co-localized with the Golgi apparatus (Figure 3A). Regarding protein function, all the tested genetic variants presented reduced levels of function compared with the WT (Figure 3B), with four mutants, [NM\\_001039885.2:\(p.Pro305Leu \(P305L\)](#), Y307N, [NM\\_001039885.2:p.Thr314Pro \(T314P\)](#) and C318Y presenting functional levels close to the catalytically dead NNN mutant. We could

1  
2  
3 also observe that the nature of the amino-acid modification, in addition to the amino-acid  
4 position, also impacted the function, as the same Threonine (T) residue in position 314, when  
5 modified to a Methionine (M) was still functional where modification to a Proline (P)  
6 abrogated completely the function. The modification of the Proline (P) in position 316 to  
7 either Arginine (R), Serine (S) or Threonine (T) did not change dramatically the overall  
8 function. All these results indicated that missense mutations localized between residues 300 to  
9 321 of the human FKRP protein, and which we refer to FKRP<sub>300-321</sub> region, do not seem to  
10 induce ER-retention but nevertheless give rise to non-functional or severely impaired mutant  
11 proteins in our system. Moreover, four genetic variants abrogated completely the protein  
12 function, perhaps indicative of the importance of these residues for the protein activity.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

## 31 **4. Discussion**

32  
33  
34 In this study, we evaluated the cellular localization, as well as the level of activity of FKRP  
35 proteins bearing genetic variants commonly found in patients using an overexpression system  
36 based on the HAP1 FKRP<sub>KO</sub> cell line. In this model system, we identified one genetic variant,  
37 V405L, which leads to a strict ER localization. Interestingly, this change between the two  
38 aliphatic amino acids is quite conservative and is not predicted to overly disrupt the secondary  
39 structure of the protein. It is therefore possible that the consequence will pertain on the  
40 tertiary or quaternary structure or else the corresponding residue is important for association  
41 with a protein implicated in the trafficking to the Golgi. We also identified three mutant  
42 proteins, S221R, P448L and A455D, found to be retained in the ER but which were  
43 nevertheless able to overcome this retention when overexpressed. This “leakage effect” has  
44 been previously described and seen in other misfolded proteins (Gomez-Navarro & Miller,  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 2016; Kawaguchi, Hsu, & Ng, 2010). Interestingly, these three mutants displayed normal  
4 functional levels. Additional mutants that were purely Golgi-resident presented different  
5 degrees of defect in enzymatic activity, with a few of them being enzymatically dead (P305L,  
6 Y307N, T314P and C318Y), indicating that this particular region ~~is~~might be important for  
7 the enzymatic activity of FKRP within the Golgi. Finally, some mutants behave similarly to  
8 the WT protein (Y182C and L276I) with respect to localization in the Golgi and  
9 glycosyltransferase function in our system.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20 The result obtained with the most frequent *FKRP* genetic variant L276I, which is well known  
21 to be associated with the mildest form of the disease, clearly pinpoints to one of the  
22 limitations of our cellular system. Here, the corresponding mutant is undistinguishable to WT  
23 whereas we previously showed that it presents a defect in glycosylation function *in vivo*  
24 (Gicquel et al., 2017). Clearly, the high overexpression levels, leading to the exacerbated  
25 protein escape from the ER into the Golgi, ~~do not~~may not allow the observation of subtle  
26 differences induced by this type of genetic variants. We might postulate that the L276I, as  
27 well as the Y182C mutant protein, may require extended folding times and be less readily  
28 available for the glycosylation process in skeletal muscle context. This hypothesis is  
29 supported by the fact that the L276I mutant protein was seen to interact more strongly with  
30 CNX, a molecular chaperone of the ER, than the WT (Esapa et al., 2005).

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46 Our data ~~demonstrated~~indicates that it is possible to obtain a full functionality with  
47 overexpression of proteins that are recognized as being abnormal by the QC as demonstrated  
48 by their ER localization. A recent report demonstrated the correct function of the P488L  
49 mutant protein *in vivo* (Tucker, Lu, Xiao, & Lu, 2018). The authors showed that the mutant  
50 protein was able to restore the  $\alpha$ -DG glycosylation at the muscle membrane and correction of  
51 the dystrophic phenotype when overexpressed by adeno-associated virus (AAV) injection in a  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 P448L<sup>neo-</sup> mouse model. In addition, in a more recent study, the same group showed that  
4  
5 supplementation of ribitol in drinking water of the P448L<sup>neo-</sup> mouse increased  $\alpha$ -DG  
6  
7 glycosylation (Cataldi, Lu, Blaeser, & Lu, 2018), indicating that even the endogenous P448L  
8  
9 mutant protein present in the mice might still retain some level of functionality. Altogether,  
10  
11 these different pieces of evidence support the idea that a pharmacological strategy allowing a  
12  
13 bypass of the QC might lead to a therapeutic benefit for patients with the corresponding  
14  
15 genetic variants.  
16  
17  
18  
19

20  
21 Our findings also revealed that patient genetic variants localized within the FKRP<sub>300-321</sub> region  
22  
23 of the protein, remarkably are all correctly localized in the Golgi but correspond to  
24  
25 functionally impaired proteins in our cellular model. Their correct localization indicates that,  
26  
27 after protein folding in the ER, the structure of these mutant proteins is possibly qualified as  
28  
29 being correctly folded by the QC system and the proteins are allowed to proceed further  
30  
31 towards their final destination. However, once in the Golgi, they might do-not have or fail to  
32  
33 attain the necessary features for proper function. One can think of incorrect localization  
34  
35 within the Golgi apparatus, impossibility to reach an active conformation or dimerization, or  
36  
37 impaired interaction with the substrate, the  $\alpha$ -DG glycosylation growing chain or additional  
38  
39 partners such as FKTN or Transmembrane Protein 5 (TMEM5) protein (Alhamidi et al.,  
40  
41 2011; Nishihara et al., 2018). The family of glycosyltransferases (GTs), of which FKRP is a  
42  
43 member, encompass enzymes responsible for the transfer of sugar moieties and the formation  
44  
45 of glycosidic linkages (Lairson, Henrissat, Davies, & Withers, 2008). The consensus in the  
46  
47 field is that the nucleotide-binding residues of GTs are not restricted to the characteristic DxD  
48  
49 motif, but can be also extended to amino-acids localized upstream and downstream of this  
50  
51 region (Breton & Imberty, 1999). While the FKRP<sub>300-321</sub> area is not close to the catalytic DxD  
52  
53 motif when the amino-acid linear sequence is considered, it is conceivable that this region is  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 required for the catalytic function and participate in the catalytic pocket through the 3D  
4 conformation. Despite our attempt, no parallel between the prediction of the deleterious score  
5 by online predictors and the severity of the disease caused by the FKRP variants was noted  
6  
7 (Supp. Table S1). Likewise, no relevant tri-dimensional model was achieved since the results  
8  
9 obtained with different prediction softwares were inconsistent. A crystallography model of  
10  
11 FKRP protein is then crucial for better understanding the mechanism of enzymatic activation  
12  
13 and function and shed a light on the structural consequences arising from the mutated  
14  
15 residues. Interestingly, to the exception of the P305L mutant which is associated to an LGMD  
16  
17 phenotype, all the identified catalytically “dead” genetic variants are associated with severe  
18  
19 phenotypes such as MEB/CMD, LIS and WWS. This information is in support of our findings  
20  
21 for the severely impaired function of these mutated proteins and might indicate that a similar  
22  
23 phenotype would be present in the human tissue context. Furthermore, patient genetic variants  
24  
25 in *FKTN*, the FKRP homologous protein that shares the same substrate and activity, were  
26  
27 described to be correctly localized in the Golgi (Tachikawa et al., 2012) while being  
28  
29 functionally impaired, (Kanagawa et al., 2016), reinforcing the relevance of our results.  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 In conclusion, we propose the following scenario of fate of the different FKRP protein  
40  
41 variants, ~~demonstrating~~suggesting the absence of correlation between the subcellular  
42  
43 localization and function of the mutant proteins (Figure 4). Overall, we believe that our  
44  
45 experimental approach, integrating the information on the mutant protein cellular localization  
46  
47 with its function, ~~is crucial~~contributes for the complete understanding of the pathogenic  
48  
49 impact of the patient mutation and of the function of the protein. Indeed, we might have  
50  
51 uncovered a particular region outside the catalytic motif that seems important for the  
52  
53 enzymatic activity of FKRP within the Golgi. Unfortunately, it is difficult to make any  
54  
55 conclusions about the severity of the disease based solely on the results obtained in our  
56  
57  
58  
59  
60

1  
2  
3 cellular model. It is highly probable that additional factors intervene to explain the phenotype  
4  
5 of the variants or combinations of variants. Lastly, the demonstration that the alteration of one  
6  
7 amino acid interfering with the proper protein folding process ~~can~~might nevertheless lead to a  
8  
9 protein with functionality ~~illustrates~~can lead to further studies about the potential for the  
10  
11 rescue of ~~these~~such proteins from degradation as a ~~likely~~ treatment option for patients.  
12  
13  
14  
15  
16  
17  
18

## 19 **Acknowledgments**

20  
21  
22  
23 We would like to thank all the Progressive Muscular Dystrophies group members. We are  
24  
25 grateful to the “Imaging and Cytometry Core Facility” of Généthon for technical support and  
26  
27 to Genopole Research, Evry, for the purchase of the equipment. The authors have no conflict  
28  
29 of interest to declare.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., . . . Sunyaev, S. R. (2010). A method and server for predicting damaging missense mutations. *Nat Methods*, 7(4), 248-249. doi: 10.1038/nmeth0410-248
- Alhamidi, M., Kjeldsen Buvang, E., Fagerheim, T., Brox, V., Lindal, S., Van Ghelue, M., & Nilssen, O. (2011). Fukutin-related protein resides in the Golgi cisternae of skeletal muscle fibres and forms disulfide-linked homodimers via an N-terminal interaction. *PLoS One*, 6(8), e22968. doi: 10.1371/journal.pone.0022968
- Barresi, R., & Campbell, K. P. (2006). Dystroglycan: from biosynthesis to pathogenesis of human disease. *J Cell Sci*, 119(Pt 2), 199-207.
- Beltran-Valero de Bernabe, D. (2004). Mutations in the FKR gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. *Journal of Medical Genetics*, 41(5), e61-e61. doi: 10.1136/jmg.2003.013870
- Bolte, S., & Cordelieres, F. P. (2006). A guided tour into subcellular colocalization analysis in light microscopy. *J Microsc*, 224(Pt 3), 213-232. doi: 10.1111/j.1365-2818.2006.01706.x
- Bouchet, C., Gonzales, M., Vuillaumier-Barrot, S., Devisme, L., Lebizec, C., Alanio, E., . . . Seta, N. (2007). Molecular heterogeneity in fetal forms of type II lissencephaly. *Hum Mutat*, 28(10), 1020-1027. doi: 10.1002/humu.20561
- Breton, C., & Imberty, A. (1999). Structure/function studies of glycosyltransferases. *Curr Opin Struct Biol*, 9(5), 563-571.
- Brockington, M., Blake, D. J., Prandini, P., Brown, S. C., Torelli, S., Benson, M. A., . . . Muntoni, F. (2001). Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. [Case Reports  
Research Support, Non-U.S. Gov't]. *Am J Hum Genet*, 69(6), 1198-1209. doi: 10.1086/324412
- Carotti, M., Marsolier, J., Soardi, M., Bianchini, E., Gomiero, C., Fecchio, C., . . . Sandona, D. (2018). Repairing folding-defective alpha-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D. *Hum Mol Genet*, 27(6), 969-984. doi: 10.1093/hmg/ddy013
- Cataldi, M. P., Lu, P., Blaeser, A., & Lu, Q. L. (2018). Ribitol restores functionally glycosylated alpha-dystroglycan and improves muscle function in dystrophic FKR-mutant mice. *Nat Commun*, 9(1), 3448. doi: 10.1038/s41467-018-05990-z

- 1  
2  
3 Chen, X., Zaro, J. L., & Shen, W. C. (2013). Fusion protein linkers: property, design and  
4 functionality. *Adv Drug Deliv Rev*, 65(10), 1357-1369. doi:  
5 10.1016/j.addr.2012.09.039  
6  
7  
8 Choi, Y., Sims, G. E., Murphy, S., Miller, J. R., & Chan, A. P. (2012). Predicting the  
9 functional effect of amino acid substitutions and indels. *PLoS One*, 7(10), e46688. doi:  
10 10.1371/journal.pone.0046688  
11  
12 de Paula, F., Vieira, N., Starling, A., Yamamoto, L. U., Lima, B., de Cassia Pavanello, R., . . .  
13 Zatz, M. (2003). Asymptomatic carriers for homozygous novel mutations in the FKRP  
14 gene: the other end of the spectrum. *Eur J Hum Genet*, 11(12), 923-930. doi:  
15 10.1038/sj.ejhg.5201066  
16  
17 Dolatshad, N. F., Brockington, M., Torelli, S., Skordis, L., Wever, U., Wells, D. J., . . .  
18 Brown, S. C. (2005). Mutated fukutin-related protein (FKRP) localises as wild type in  
19 differentiated muscle cells. [Research Support, Non-U.S. Gov't]. *Exp Cell Res*, 309(2),  
20 370-378. doi: 10.1016/j.yexcr.2005.06.017  
21  
22  
23 Endo, Y., Dong, M., Noguchi, S., Ogawa, M., Hayashi, Y. K., Kuru, S., . . . Nishino, I.  
24 (2015). Milder forms of muscular dystrophy associated with POMGNT2 mutations.  
25 *Neurol Genet*, 1(4), e33. doi: 10.1212/nxg.0000000000000033  
26  
27  
28 Ervasti, J. M., & Campbell, K. P. (1993). A role for the dystrophin-glycoprotein complex as a  
29 transmembrane linker between laminin and actin. *J Cell Biol*, 122(4), 809-823.  
30  
31 Esapa, C. T., Benson, M. A., Schroder, J. E., Martin-Rendon, E., Brockington, M., Brown, S.  
32 C., . . . Blake, D. J. (2002). Functional requirements for fukutin-related protein in the  
33 Golgi apparatus. *Hum Mol Genet*, 11(26), 3319-3331.  
34  
35 Esapa, C. T., McIlhinney, R. A., & Blake, D. J. (2005). Fukutin-related protein mutations that  
36 cause congenital muscular dystrophy result in ER-retention of the mutant protein in  
37 cultured cells. *Hum Mol Genet*, 14(2), 295-305. doi: 10.1093/hmg/ddi026  
38  
39  
40 Gerin, I., Ury, B., Breloy, I., Bouchet-Seraphin, C., Bolsee, J., Halbout, M., . . . Bommer, G.  
41 T. (2016). ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol  
42 phosphate onto alpha-dystroglycan. *Nat Commun*, 7, 11534. doi:  
43 10.1038/ncomms11534  
44  
45  
46 Gicquel, E., Maizonnier, N., Foltz, S. J., Martin, W. J., Bourg, N., Svinartchouk, F., . . .  
47 Richard, I. (2017). AAV-mediated transfer of FKRP shows therapeutic efficacy in a  
48 murine model but requires control of gene expression. *Hum Mol Genet*, 26(10), 1952-  
49 1965. doi: 10.1093/hmg/ddx066  
50  
51  
52 Gomez-Navarro, N., & Miller, E. (2016). Protein sorting at the ER-Golgi interface. *J Cell*  
53 *Biol*, 215(6), 769-778. doi: 10.1083/jcb.201610031  
54  
55  
56 Guglieri, M., Straub, V., Bushby, K., & Lochmuller, H. (2008). Limb-girdle muscular  
57 dystrophies. *Curr Opin Neurol*, 21(5), 576-584. doi:  
58 10.1097/WCO.0b013e32830efdc2  
59  
60

- 1  
2  
3 Hohenester, E., Tisi, D., Talts, J. F., & Timpl, R. (1999). The crystal structure of a laminin G-  
4 like module reveals the molecular basis of alpha-dystroglycan binding to laminins,  
5 perlecan, and agrin. [Research Support, Non-U.S. Gov't]. *Mol Cell*, *4*(5), 783-792.  
6  
7 Imae, R., Manya, H., Tsumoto, H., Osumi, K., Tanaka, T., Mizuno, M., . . . Endo, T. (2018).  
8 CDP-glycerol inhibits the synthesis of the functional O-mannosyl glycan of alpha-  
9 dystroglycan. *J Biol Chem*, *293*(31), 12186-12198. doi: 10.1074/jbc.RA118.003197  
10  
11  
12 Kanagawa, M., Kobayashi, K., Tajiri, M., Manya, H., Kuga, A., Yamaguchi, Y., . . . Toda, T.  
13 (2016). Identification of a Post-translational Modification with Ribitol-Phosphate and  
14 Its Defect in Muscular Dystrophy. *Cell Rep*, *14*(9), 2209-2223. doi:  
15 10.1016/j.celrep.2016.02.017  
16  
17 Kawaguchi, S., Hsu, C. L., & Ng, D. T. (2010). Interplay of substrate retention and export  
18 signals in endoplasmic reticulum quality control. *PLoS One*, *5*(11), e15532. doi:  
19 10.1371/journal.pone.0015532  
20  
21  
22 Kefi, M., Amouri, R., Chabrak, S., Mechmeche, R., & Hentati, F. (2008). Variable cardiac  
23 involvement in Tunisian siblings harboring FKRП gene mutations. *Neuropediatrics*,  
24 *39*(2), 113-115. doi: 10.1055/s-2008-1081465  
25  
26 Keramaris-Vrantsis, E., Lu, P. J., Doran, T., Zillmer, A., Ashar, J., Esapa, C. T., . . . Lu, Q. L.  
27 (2007). Fukutin-related protein localizes to the Golgi apparatus and mutations lead to  
28 mislocalization in muscle in vivo. [Research Support, Non-U.S. Gov't]. *Muscle Nerve*,  
29 *36*(4), 455-465. doi: 10.1002/mus.20833  
30  
31  
32 Lairson, L. L., Henrissat, B., Davies, G. J., & Withers, S. G. (2008). Glycosyltransferases:  
33 structures, functions, and mechanisms. *Annu Rev Biochem*, *77*, 521-555. doi:  
34 10.1146/annurev.biochem.76.061005.092322  
35  
36  
37 Louhichi, N., Triki, C., Quijano-Roy, S., Richard, P., Makri, S., Meziou, M., . . . Fakhfakh, F.  
38 (2004). New FKRП mutations causing congenital muscular dystrophy associated with  
39 mental retardation and central nervous system abnormalities. Identification of a  
40 founder mutation in Tunisian families. *Neurogenetics*, *5*(1), 27-34. doi:  
41 10.1007/s10048-003-0165-9  
42  
43  
44 Matsumoto, H., Noguchi, S., Sugie, K., Ogawa, M., Murayama, K., Hayashi, Y. K., &  
45 Nishino, I. (2004). Subcellular localization of fukutin and fukutin-related protein in  
46 muscle cells. [Research Support, Non-U.S. Gov't]. *J Biochem*, *135*(6), 709-712. doi:  
47 10.1093/jb/mvh086  
48  
49  
50 Mercuri, E., Brockington, M., Straub, V., Quijano-Roy, S., Yuva, Y., Herrmann, R., . . .  
51 Muntoni, F. (2003). Phenotypic spectrum associated with mutations in the fukutin-  
52 related protein gene. *Ann Neurol*, *53*(4), 537-542. doi: 10.1002/ana.10559  
53  
54  
55 Mercuri, E., Topaloglu, H., Brockington, M., Berardinelli, A., Pichiecchio, A., Santorelli, F., .  
56 . . . Muntoni, F. (2006). Spectrum of brain changes in patients with congenital muscular  
57 dystrophy and FKRП gene mutations. *Arch Neurol*, *63*(2), 251-257. doi:  
58 10.1001/archneur.63.2.251  
59  
60

- 1  
2  
3 Nishihara, R., Kobayashi, K., Imae, R., Tsumoto, H., Manya, H., Mizuno, M., . . . Toda, T.  
4 (2018). Cell endogenous activities of fukutin and FKRPs coexist with the ribitol  
5 xylosyltransferase, TMEM5. *Biochem Biophys Res Commun*, 497(4), 1025-1030. doi:  
6 10.1016/j.bbrc.2018.02.162  
7  
8 Quijano-Roy, S., Marti-Carrera, I., Makri, S., Mayer, M., Maugenre, S., Richard, P., . . .  
9 Carlier, R. Y. (2006). Brain MRI abnormalities in muscular dystrophy due to FKRPs  
10 mutations. *Brain Dev*, 28(4), 232-242. doi: 10.1016/j.braindev.2005.08.003  
11  
12  
13 Reva, B., Antipin, Y., & Sander, C. (2011). Predicting the functional impact of protein  
14 mutations: application to cancer genomics. *Nucleic Acids Res*, 39(17), e118. doi:  
15 10.1093/nar/gkr407  
16  
17 Richard, I., Laurent, J. P., Cirak, S., & Vissing, J. (2016). 216th ENMC international  
18 workshop: Clinical readiness in FKRPs related myopathies January 15-17, 2016  
19 Naarden, The Netherlands. *Neuromuscul Disord*, 26(10), 717-724. doi:  
20 10.1016/j.nmd.2016.08.012  
21  
22  
23 Riemersma, M., Froese, D. S., van Tol, W., Engelke, U. F., Kopec, J., van Scherpenzeel, M., .  
24 . . . Lefeber, D. J. (2015). Human ISPD Is a Cytidyltransferase Required for  
25 Dystroglycan O-Mannosylation. [Research Support, Non-U.S. Gov't]. *Chem Biol*,  
26 22(12), 1643-1652. doi: 10.1016/j.chembiol.2015.10.014  
27  
28  
29 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., . . .  
30 Cardona, A. (2012). Fiji: an open-source platform for biological-image analysis. *Nat*  
31 *Methods*, 9(7), 676-682. doi: 10.1038/nmeth.2019  
32  
33  
34 Soheili, T., Gicquel, E., Poupiot, J., N'Guyen, L., Le Roy, F., Bartoli, M., & Richard, I.  
35 (2012). Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum  
36 quality control is associated with minimal structural modifications. *Hum Mutat*, 33(2),  
37 429-439. doi: 10.1002/humu.21659  
38  
39 Stevens, E., Torelli, S., Feng, L., Phadke, R., Walter, M. C., Schneiderat, P., . . . Muntoni, F.  
40 (2013). Flow cytometry for the analysis of alpha-dystroglycan glycosylation in  
41 fibroblasts from patients with dystroglycanopathies. *PLoS One*, 8(7), e68958. doi:  
42 10.1371/journal.pone.0068958  
43  
44  
45 Tachikawa, M., Kanagawa, M., Yu, C. C., Kobayashi, K., & Toda, T. (2012). Mislocalization  
46 of fukutin protein by disease-causing missense mutations can be rescued with  
47 treatments directed at folding amelioration. [Research Support, Non-U.S. Gov't]. *J*  
48 *Biol Chem*, 287(11), 8398-8406. doi: 10.1074/jbc.M111.300905  
49  
50 Talts, J. F., Andac, Z., Gohring, W., Brancaccio, A., & Timpl, R. (1999). Binding of the G  
51 domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides,  
52 alpha-dystroglycan and several extracellular matrix proteins. [Research Support, Non-  
53 U.S. Gov't]. *EMBO J*, 18(4), 863-870. doi: 10.1093/emboj/18.4.863  
54  
55  
56 Tisi, D., Talts, J. F., Timpl, R., & Hohenester, E. (2000). Structure of the C-terminal laminin  
57 G-like domain pair of the laminin alpha2 chain harbouring binding sites for alpha-  
58 dystroglycan and heparin. [Comparative Study  
59  
60

- 1  
2  
3 Research Support, Non-U.S. Gov't]. *EMBO J*, 19(7), 1432-1440. doi:  
4 10.1093/emboj/19.7.1432  
5  
6 Topaloglu, H., Brockington, M., Yuva, Y., Talim, B., Haliloglu, G., Blake, D., . . . Muntoni,  
7 F. (2003). FKRP gene mutations cause congenital muscular dystrophy, mental  
8 retardation, and cerebellar cysts. *Neurology*, 60(6), 988-992.  
9  
10 Torelli, S., Brown, S. C., Brockington, M., Dolatshad, N. F., Jimenez, C., Skordis, L., . . .  
11 Muntoni, F. (2005). Sub-cellular localisation of fukutin related protein in different cell  
12 lines and in the muscle of patients with MDC1C and LGMD2I. [Comparative Study  
13  
14 Research Support, Non-U.S. Gov't]. *Neuromuscul Disord*, 15(12), 836-843. doi:  
15 10.1016/j.nmd.2005.09.004  
16  
17 Tucker, J. D., Lu, P. J., Xiao, X., & Lu, Q. L. (2018). Overexpression of Mutant FKRP  
18 Restores Functional Glycosylation and Improves Dystrophic Phenotype in FKRP  
19 Mutant Mice. *Mol Ther Nucleic Acids*, 11, 216-227. doi: 10.1016/j.omtn.2018.02.008  
20  
21 von der Hagen, M., Kaindl, A. M., Koehler, K., Mitzscherling, P., Hausler, H. J., Stoltenburg-  
22 Didinger, G., & Huebner, A. (2006). Limb girdle muscular dystrophy type 2I caused  
23 by a novel missense mutation in the FKRP gene presenting as acute virus-associated  
24 myositis in infancy. *Eur J Pediatr*, 165(1), 62-63. doi: 10.1007/s00431-005-1752-6  
25  
26 Wahbi, K., Meune, C., Hamouda el, H., Stojkovic, T., Laforet, P., Becane, H. M., . . . Duboc,  
27 D. (2008). Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an  
28 echography, Holter ECG and magnetic resonance imaging study. *Neuromuscul*  
29 *Disord*, 18(8), 650-655. doi: 10.1016/j.nmd.2008.06.365  
30  
31 Walter, M. C., Petersen, J. A., Stucka, R., Fischer, D., Schroder, R., Vorgerd, M., . . .  
32 Lochmuller, H. (2004). FKRP (826C>A) frequently causes limb-girdle muscular  
33 dystrophy in German patients. *J Med Genet*, 41(4), e50.  
34  
35 Yamamoto, L. U., Velloso, F. J., Lima, B. L., Fogaca, L. L., de Paula, F., Vieira, N. M., . . .  
36 Vainzof, M. (2008). Muscle protein alterations in LGMD2I patients with different  
37 mutations in the Fukutin-related protein gene. *J Histochem Cytochem*, 56(11), 995-  
38 1001. doi: 10.1369/jhc.2008.951772  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure legends

### Figure 1. Cellular characterization of HAP1 WT and HAP1 FKRP-KO cell lines. (A)

Cellular morphology and endogenous FKRP cellular localization. Endogenous FKRP protein was detected in HAP1 WT cells (top panels), where the signal co-localized with the *cis*-Golgi Marker GM130 and the *trans*-Golgi marker TGN46, and was absent at these locations in HAP1 FKRP<sub>KO</sub> cells (bottom panels). Nuclei are labelled by DAPI staining. Scale bars: 30 $\mu$ m (bright-field), 10 $\mu$ m (fluorescence). (B) Small cytoplasmic volume and perturbed membrane morphology in HAP1 FKRP KO cells was observed compared to the HAP1 WT control cell line, based on the IF against membrane  $\beta$ -integrin and WGA. Image magnifications are presented in the right panels. Nuclei are labelled by DAPI staining. Scale bars: 20 $\mu$ m and 10 $\mu$ m for zooms (C) Characterization of  $\alpha$ -DG functional glycosylation in the two cell lines. The specific glycosylation, detected through the IIH6 antibody, was present in HAP1 WT but not in HAP1 FKRP KO as observed by confocal imaging. (D) Flow cytometry quantification of  $\alpha$ -DG functional glycosylation of HAP1-WT and HAP1 FKRP KO labelled with secondary antibody alone (II) or in combination with IIH6 primary antibody against  $\alpha$ -DG functional glycosylation (I + II). \*\*\*\* $p \leq 0.0001$ .

### Figure 2. Cellular localization and functional characterization of FKRP mutant proteins

in HAP1 FKRP KO cells. (A) FKRPmCh mutant proteins cellular localization after IF for the *trans*-Golgi compartment (TGN46). Nuclei are labelled by DAPI staining. Scale bar: 5 $\mu$ m.

(B) Functional characterization of FKRP mutant proteins through detection of  $\alpha$ -DG functional glycosylation after lentivirus transduction in HAP1 FKRP KO cells. In this condition, the low copy number achieved allows observation along time. The levels of the specific  $\alpha$ -DG glycosylation, as well as the levels of mCherry signal as a measure of

FKRPMCh protein production, were followed and quantified through time. The levels of glycosylation were assessed only for the mCherry positive population representing the successfully transfected cells. Data is presented as the integrated Mean Fluorescence Intensity (iMFI = MFI \* % positive cells) values in arbitrary units (A.U.) within this mCherry population.

**Figure 3. Cellular localization and functional characterization of FKRPs with missense mutations localized between residue 300 and 328.** (A) FKRPMCh mutant proteins cellular localization by IF for the *trans*-Golgi compartment (TGN46) after transfection in HAP1 FKRPs KO cells. The mCherry signal of the fusion proteins specifically co-localized with the *trans*-Golgi for FKRPs WT and all the mutants within residue 300 and 321. Mutant Y328S displayed a *trans*-Golgi co-localization as well as a cytoplasmic signal corresponding to the ER. Nuclei are labelled by DAPI staining. Scale bar: 5µm. (B) Functional characterization of FKRPs mutant proteins through detection of  $\alpha$ -DG functional glycosylation after transfection in HAP1 FKRPs KO cells. The levels of glycosylation were assessed only for the mCherry positive population representing the successfully transfected cells. The functional level of the catalytically dead NNN mutant protein is represented as a dashed line. Data is presented as relative iMFI (MFI \* % positive cells) values in arbitrary units (A.U.). ns= non-significant, \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ .

**Figure 4. Graphic model depicting the-proposed steps and final outcomes of normal and abnormal FKRPs protein folding/function in physiological conditions *in vivo*.** (A) Normal physiological condition. 1) FKRPs is correctly folded in the ER; 2) FKRPs is trafficked to the *trans*-Golgi; 3) FKRPs transfers Rbo-5P to  $\alpha$ -DG glycosylation chain; 4)  $\alpha$ -DG is functionally glycosylated at the membrane; 5) Correct ECM binding ensures sarcolemma integrity. (B) Patient with missense mutation in FKRPs- protein is retained in the ER. 1) Mutation in FKRPs

1  
2  
3 lead to ER-retained misfolded protein; 2) FKRP protein is not able to traffic correctly to the  
4 Golgi; 3) The  $\alpha$ -DG glycosylation chain is not extended; 4) Defects in ECM binding lead to  
5 membrane fragility and muscle dystrophy. (C) Patient with missense mutation in FKRP-  
6 protein is not functionally active. 1) FKRP is correctly folded in the ER; 2) FKRP is  
7 trafficked to the *trans*-Golgi; 3) FKRP does not achieve functional conformation in the Golgi  
8 and fails to transfers Rbo-5P to  $\alpha$ -DG glycosylation chain; 4) The  $\alpha$ -DG glycosylation chain is  
9 not extended; 5) Defects in ECM binding lead to membrane fragility and muscle dystrophy.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

**Table 1. Description of the studied FKRP patient variants.** The information presented includes the associated pathology, number of case reports and the corresponding references (Leiden Muscular Dystrophy pages; [www.dmd.nl/](http://www.dmd.nl/)). **(A)** FKRP missense mutants used in the subcellular localization and functional studies. **(B)** FKRP missense mutations localized between protein residues 300 and 328. The human *FKRP* gene (Gene ID: 79147, NM\_001039885.2, CCDS12691.1) is used and gene variants are described using HGVS-nomenclature (<http://varnomen.hgvs.org>). CMD = Congenital Muscular Dystrophy, MEB = Muscle-Eye-Brain disease, WWS = Walker-Warburg Syndrome, LIS = Lissencephaly, LGMD2I = Limb-Girdle Muscular Dystrophy type 2I.

**A.**


Human genetic variants	Pathology†	# Reports†	References
<a href="#">NM_001039885.2:c.545A&gt;G</a> <del>(NM_001039885.2:p.Tyr182Cys</del> <del>;(Y182C)</del>	LGMD2I	6	(de Paula et al., 2003; Wahbi et al., 2008; Yamamoto et al., 2008)
<a href="#">NM_001039885.2:c.663C&gt;A</a> <a href="#">NM_001039885.2:(p.Ser221Arg;</a>	CMD	2	(Mercuri et al., 2006; Topaloglu et al., 2003)
<a href="#">NM_001039885.2:c.826C&gt;A</a> <a href="#">NM_001039885.2:(p.Leu276Ile;</a> <a href="#">(L276I)</a>	LGMD2I	240	Several reports
<a href="#">NM_001039885.2:c.899T&gt;C</a> <a href="#">NM_001039885.2:(p.Val300Ala;</a> <a href="#">(V300A)</a>	LGMD2I	5	(de Paula et al., 2003; Walter et al., 2004; Yamamoto et al., 2008)
<a href="#">NM_001039885.2:c.1213G&gt;T</a> <a href="#">NM_001039885.2:(p.Val405Leu;</a> <a href="#">(P405L,V405L)</a>	CMD	1	(Louhichi et al., 2004)
<a href="#">NM_001039885.2:c.1343C&gt;T</a> <a href="#">NM_001039885.2:(p.Pro448Leu;</a> <a href="#">(P448L)</a>	CMD	3	(Brockington et al., 2001; Dolatshad et al., 2005; Mercuri et al., 2003)
<a href="#">NM_001039885.2:c.1364C&gt;A</a> <a href="#">NM_001039885.2:(p.Ala455Asp;</a> <a href="#">(A455D)</a>	LGMD2I/CMD	14	(Louhichi et al., 2004) (Kefi, Amouri, Chabrak, Mechmeche, & Hentati, 2008;
†Leiden Muscular Dystrophy pages			

**B.**


Human genetic variants	Pathology†	# Reports†	References
------------------------	------------	------------	------------

<a href="#">NM_001039885.2:c.914C&gt;T</a> <a href="#">NM_001039885.2:(p.Pro305Leu; (P305L)</a>	LGMD2I	2	-
<a href="#">NM_001039885.2:c.919T&gt;A</a> <a href="#">NM_001039885.2:(p.Tyr307Asn; (Y307N)</a>	MEB/CMD	10	(Beltran-Valero de Bernabe, 2004) (Mercuri et al., 2006; Torelli et al., 2005) (Wahbi et
<a href="#">NM_001039885.2:c.926A&gt;G</a> <a href="#">NM_001039885.2:(p.Tyr309Cys; (Y309C)</a>	-	1	(Brockington et al., 2001; Mercuri et al., 2003; Torelli et al., 2005)
<a href="#">NM_001039885.2:c.934C&gt;T</a> <a href="#">NM_001039885.2:(p.Arg312Cys; (R312C)</a>	-	1	(Brockington et al., 2001)
<a href="#">NM_001039885.2:c.941C&gt;T</a> <a href="#">NM_001039885.2:(p.Thr314Met; (T314M)</a>	CMD/LGMD2I	6	-
<a href="#">NM_001039885.2:c.940A&gt;C</a> <a href="#">(NM_001039885.2:p.Thr314Pro (T314P)</a>	LIS	2	(Bouchet et al., 2007)
<a href="#">NM_001039885.2:c.946C&gt;A</a> <a href="#">NM_001039885.2:(p.Pro316Thr; (P316T)</a>	CMD/LGMD2I	4	(Mercuri et al., 2006; Topaloglu et al., 2003)
<a href="#">NM_001039885.2:c.946C&gt;T</a> <a href="#">NM_001039885.2:(p.Pro316Ser; (P316S)</a>	-	1	(Mercuri et al., 2003)
<a href="#">NM_001039885.2:c.947C&gt;G</a> <a href="#">NM_001039885.2:(p.Pro316Arg; (P316R)</a>	CMD/LGMD2I	3	(Brockington et al., 2001; Quijano-Roy et al., 2006)
<a href="#">NM_001039885.2:c.953G&gt;A</a> <a href="#">NM_001039885.2:(p.Cys318Tyr; (C318Y)</a>	WWS	2	(Beltran-Valero de Bernabe, 2004) (Mercuri et al., 2006)
<a href="#">NM_001039885.2:c.956T&gt;G</a> <a href="#">NM_001039885.2:(p.Leu319Arg; (L319R)</a>	LGMD2I	1	(Guglieri, Straub, Bushby, & Lochmuller, 2008)
<a href="#">NM_001039885.2:c.962C&gt;A</a> <a href="#">NM_001039885.2:(p.Ala321Glu; (A321E)</a>	LGMD2I	1	(von der Hagen et al., 2006)
<a href="#">NM_001039885.2:c.983A&gt;C</a> <a href="#">NM_001039885.2:(p.Tyr328Ser; (Y328S)</a>	CMD/LGMD2I	2	(Brockington et al., 2001; Quijano-Roy et al., 2006; Wahbi et al., 2008)
†Leiden Muscular Dystrophy pages			


A



B




C



57  
58  
59  
60


**Supp. Figure 1. Characterization of the FKRPMCh fusion protein.**

1  
2  
3 **(A)** Correct co-localization of the mCherry signal in the FKRPmCh protein and FKRP  
4 labelling confirms the integrity of the fusion protein. Nuclei are labelled by DAPI staining.  
5 Scale bar: 5µm. **(B)** Co-localization of the mCherry signal in the FKRPmCh protein with the  
6 *cis*- (GM130) and *trans*-Golgi (TGN46) labelling confirming that the addition of the mCherry  
7 fluorescent reporter did not interfere with the normal FKRP protein traffic. Pearson  
8 correlation coefficients between the red (mCh) and green (GM130/TGN46) calculated using  
9 the JACoP plugin for ImageJ are presented for the magnified images. Nuclei are labelled by  
10 DAPI staining. Scale bar: 10µm. **(C)** Confocal imaging after labelling of  $\alpha$ -DG functional  
11 glycosylation (IIH6) in non-permeabilized conditions and transfection of FKRPmCh-WT in  
12 HAP1 FKRP KO cells. Nuclei are labelled by DAPI staining. Scale bar: 10µm.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Supp. Figure 2. ER-retention of FKRP mutant proteins.**


FKRPMCh WT and V405L mutant protein cellular localization after IF staining for the ER compartment (CNX). The mCherry signal of the fusion proteins specifically co-localized with the ER for FKRP V405L, as an example, confirming that the cytoplasmic signals observed represents ER-retained mutant proteins. Nuclei are labelled by DAPI staining. Scale bar: 10 $\mu$ m.



**Supp. Figure 3. Flow cytometry data and gates in HAP1-WT and HAP1 FKRP KO cells.**

1  
2  
3 Flow cytometry data of HAP1-WT, HAP1 FKRP KO and HAP1 FKRP KO cells transfected  
4 with FKRPmCh WT construct labelled with A488 secondary antibody alone (II) or in  
5 combination with IIH6 primary antibody against  $\alpha$ -DG functional glycosylation (I + II). Cell  
6 gates were defined using the appropriate experimental controls. mCherry (mCh) and A488  
7 signal intensities are shown in axis. The data shows that the intensity of labelling (A488) of  
8 the FKRPmCh WT transfected HAP1 FKRP KO cells are in the range of the levels of  
9 intensity seen in the HAP1 WT cells (HAP1 WT I+II).  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review



**Supp. Figure 34. Function of FKR mutant proteins at 45h of expression.**

Functional characterization of FKR mutant proteins through detection of  $\alpha$ -DG functional glycosylation. Only functional levels at 45h are depicted confirming that the mutant proteins, E2E5, V300A and V405L, display levels comparable to the catalytically dead NNN mutant protein. The levels of glycosylation were assessed only for the mCherry positive population representing the successfully transfected cells. Data is presented as relative iMFI (MFI \* % positive cells) values in arbitrary units (A.U.). ns= non-significant, \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ .

Variant	PolyPhen-2	PROVEAN		MutationAssessor	
	Prediction	Prediction	Score	Func. Impact	FI score
Y182C	Benign	Deleterious	-4.767	Low	1.385
S221R	Probably damaging	Neutral	-2.367	Low	1.445
L276I	Possibly damaging	Neutral	-0.849	Low	1.355
V300A	Possibly damaging	Deleterious	-3.219	Low	1.87
V405L	Probably damaging	Neutral	-2.372	Medium	2.35
P448L	Probably damaging	Deleterious	-8.165	Medium	2.465
A455D	Probably damaging	Deleterious	-3.969	Medium	2.005
P305L	Probably damaging	Deleterious	-8.796	Medium	2.02
Y307N	Probably damaging	Deleterious	-7.733	Medium	2.02
Y309C	Probably damaging	Deleterious	-6.507	Low	1.87
R312C	Probably damaging	Deleterious	-5.987	Low	1.73
T314M	Probably damaging	Deleterious	-4.744	Medium	2.455
T314P	Probably damaging	Deleterious	-5.211	Medium	3.005
P316T	Probably damaging	Deleterious	-6.404	Medium	3.035
P316S	Probably damaging	Deleterious	-6.404	Medium	3.035
P316R	Probably damaging	Deleterious	-7.533	Medium	2.69
C318Y	Probably damaging	Deleterious	-9.426	Medium	3.14
L319R	Probably damaging	Deleterious	-4.198	Medium	2.51
A321E	Probably damaging	Neutral	-1.115	Low	1.91
Y328S	Possibly damaging	Deleterious	-3.526	Low	1.925

**Supp. Table 1. Prediction scores of deleteriousness for FKR protein variants. The prediction scores of three independent online predictors (PolyPhen-2, PROVEAN and MutationAssessor) are presented for the human FKR protein with the introduced specific variants.**

Input	Errors and warnings	AccNo	Genesymbol	Variant	Reference Sequence	Start	Descr.
Protein Descr.	Genomic Reference	Protein Descr.	GeneSymbol	Coding DNA Descr.	GeneSymbol	Affected	
Transcripts	Affected Proteins	Coding Reference	Protein Reference	Restriction Sites Created	Restriction Sites Deleted		
NM_001039885.2:c.545A>G		NM_001039885.2	FKRP_v001	c.545A>G			
n.894A>G	c.545A>G	p.(Tyr182Cys)	FKRP_v001:c.545A>G				
FKRP_v001:p.(Tyr182Cys)		NM_001039885.2	NP_001034974.1				
NM_001039885.2(FKRP_v001):c.545A>G		NM_001039885.2(FKRP_i001):p.(Tyr182Cys)					
MspA1I							
NM_001039885.2:c.663C>A		NM_001039885.2	FKRP_v001	c.663C>A			
n.1012C>A	c.663C>A	p.(Ser221Arg)	FKRP_v001:c.663C>A				
FKRP_v001:p.(Ser221Arg)		NM_001039885.2	NP_001034974.1				
NM_001039885.2(FKRP_v001):c.663C>A		NM_001039885.2(FKRP_i001):p.(Ser221Arg)					
"Hinfl,MlyI,Plcl"	MnII						
NM_001039885.2:c.826C>A		NM_001039885.2	FKRP_v001	c.826C>A			
n.1175C>A	c.826C>A	p.(Leu276Ile)	FKRP_v001:c.826C>A				
FKRP_v001:p.(Leu276Ile)		NM_001039885.2	NP_001034974.1				
NM_001039885.2(FKRP_v001):c.826C>A		NM_001039885.2(FKRP_i001):p.(Leu276Ile)					
"Bfal,Ecil"							
NM_001039885.2:c.899T>C		NM_001039885.2	FKRP_v001	c.899T>C			
n.1248T>C	c.899T>C	p.(Val300Ala)	FKRP_v001:c.899T>C				
FKRP_v001:p.(Val300Ala)		NM_001039885.2	NP_001034974.1				
NM_001039885.2(FKRP_v001):c.899T>C		NM_001039885.2(FKRP_i001):p.(Val300Ala)					
"MspA1I,SacII"	HpyCH4III						
NM_001039885.2:c.1213G>T		NM_001039885.2	FKRP_v001	c.1213G>T			
n.1562G>T	c.1213G>T	p.(Val405Leu)	FKRP_v001:c.1213G>T				
FKRP_v001:p.(Val405Leu)		NM_001039885.2	NP_001034974.1				
NM_001039885.2(FKRP_v001):c.1213G>T		NM_001039885.2(FKRP_i001):p.(Val405Leu)					
"BsgI,BstUI"							
NM_001039885.2:c.1343C>T		NM_001039885.2	FKRP_v001	c.1343C>T			
n.1692C>T	c.1343C>T	p.(Pro448Leu)	FKRP_v001:c.1343C>T				
FKRP_v001:p.(Pro448Leu)		NM_001039885.2	NP_001034974.1				
NM_001039885.2(FKRP_v001):c.1343C>T		NM_001039885.2(FKRP_i001):p.(Pro448Leu)					
"AluI,PvuII"	Acil						
NM_001039885.2:c.1364C>A		NM_001039885.2	FKRP_v001	c.1364C>A			
n.1713C>A	c.1364C>A	p.(Ala455Asp)	FKRP_v001:c.1364C>A				
FKRP_v001:p.(Ala455Asp)		NM_001039885.2	NP_001034974.1				
NM_001039885.2(FKRP_v001):c.1364C>A		NM_001039885.2(FKRP_i001):p.(Ala455Asp)					
BceAI	"BsrFI,HpaII,MspI,NaeI,NgoMIV"						
NM_001039885.2:c.914C>T		NM_001039885.2	FKRP_v001	c.914C>T			
n.1263C>T	c.914C>T	p.(Pro305Leu)	FKRP_v001:c.914C>T				
FKRP_v001:p.(Pro305Leu)		NM_001039885.2	NP_001034974.1				

1  
2  
3 NM\_001039885.2(FKRP\_v001):c.914C>T NM\_001039885.2(FKRP\_i001):p.(Pro305Leu)  
4 "Acil,Faul"

5  
6 NM\_001039885.2:c.919T>A NM\_001039885.2 FKRP\_v001 c.919T>A  
7 n.1268T>A c.919T>A p.(Tyr307Asn) FKRP\_v001:c.919T>A  
8 FKRP\_v001:p.(Tyr307Asn) NM\_001039885.2 NP\_001034974.1  
9 NM\_001039885.2(FKRP\_v001):c.919T>A NM\_001039885.2(FKRP\_i001):p.(Tyr307Asn)  
10  
11

12  
13 NM\_001039885.2:c.926A>G NM\_001039885.2 FKRP\_v001 c.926A>G  
14 n.1275A>G c.926A>G p.(Tyr309Cys) FKRP\_v001:c.926A>G  
15 FKRP\_v001:p.(Tyr309Cys) NM\_001039885.2 NP\_001034974.1  
16 NM\_001039885.2(FKRP\_v001):c.926A>G NM\_001039885.2(FKRP\_i001):p.(Tyr309Cys)  
17  
18

19  
20 NM\_001039885.2:c.934C>T NM\_001039885.2 FKRP\_v001 c.934C>T  
21 n.1283C>T c.934C>T p.(Arg312Cys) FKRP\_v001:c.934C>T  
22 FKRP\_v001:p.(Arg312Cys) NM\_001039885.2 NP\_001034974.1  
23 NM\_001039885.2(FKRP\_v001):c.934C>T NM\_001039885.2(FKRP\_i001):p.(Arg312Cys)  
24 "AfeI,Haell,HhaI,HinP1I,MwoI"  
25

26  
27 NM\_001039885.2:c.941C>T NM\_001039885.2 FKRP\_v001 c.941C>T  
28 n.1290C>T c.941C>T p.(Thr314Met) FKRP\_v001:c.941C>T  
29 FKRP\_v001:p.(Thr314Met) NM\_001039885.2 NP\_001034974.1  
30 NM\_001039885.2(FKRP\_v001):c.941C>T NM\_001039885.2(FKRP\_i001):p.(Thr314Met)  
31 "BtsCI,FokI,SfaNI" "BsaHI,HgaI"  
32

33  
34 NM\_001039885.2:c.940A>C NM\_001039885.2 FKRP\_v001 c.940A>C  
35 n.1289A>C c.940A>C p.(Thr314Pro) FKRP\_v001:c.940A>C  
36 FKRP\_v001:p.(Thr314Pro) NM\_001039885.2 NP\_001034974.1  
37 NM\_001039885.2(FKRP\_v001):c.940A>C NM\_001039885.2(FKRP\_i001):p.(Thr314Pro)  
38 "Acil,CviKI\_1,EaeI,HaellI"  
39 "BsaHI,HgaI"

40  
41 NM\_001039885.2:c.946C>A NM\_001039885.2 FKRP\_v001 c.946C>A  
42 n.1295C>A c.946C>A p.(Pro316Thr) FKRP\_v001:c.946C>A  
43 FKRP\_v001:p.(Pro316Thr) NM\_001039885.2 NP\_001034974.1  
44 NM\_001039885.2(FKRP\_v001):c.946C>A NM\_001039885.2(FKRP\_i001):p.(Pro316Thr)  
45 "BfuAI,BspMI"

46  
47 NM\_001039885.2:c.946C>T NM\_001039885.2 FKRP\_v001 c.946C>T  
48 n.1295C>T c.946C>T p.(Pro316Ser) FKRP\_v001:c.946C>T  
49 FKRP\_v001:p.(Pro316Ser) NM\_001039885.2 NP\_001034974.1  
50 NM\_001039885.2(FKRP\_v001):c.946C>T NM\_001039885.2(FKRP\_i001):p.(Pro316Ser)  
51  
52

53  
54 NM\_001039885.2:c.947C>G NM\_001039885.2 FKRP\_v001 c.947C>G  
55 n.1296C>G c.947C>G p.(Pro316Arg) FKRP\_v001:c.947C>G  
56 FKRP\_v001:p.(Pro316Arg) NM\_001039885.2 NP\_001034974.1  
57 NM\_001039885.2(FKRP\_v001):c.947C>G NM\_001039885.2(FKRP\_i001):p.(Pro316Arg)  
58 "Acil,Faul,MspA1I"  
59  
60

1  
2  
3 NM\_001039885.2:c.953G>A NM\_001039885.2 FKRP\_v001 c.953G>A  
4 n.1302G>A c.953G>A p.(Cys318Tyr) FKRP\_v001:c.953G>A  
5 FKRP\_v001:p.(Cys318Tyr) NM\_001039885.2 NP\_001034974.1  
6 NM\_001039885.2(FKRP\_v001):c.953G>A NM\_001039885.2(FKRP\_i001):p.(Cys318Tyr)  
7 "BfuAI,BspMI"  
8  
9  
10 NM\_001039885.2:c.956T>G NM\_001039885.2 FKRP\_v001 c.956T>G  
11 n.1305T>G c.956T>G p.(Leu319Arg) FKRP\_v001:c.956T>G  
12 FKRP\_v001:p.(Leu319Arg) NM\_001039885.2 NP\_001034974.1  
13 NM\_001039885.2(FKRP\_v001):c.956T>G NM\_001039885.2(FKRP\_i001):p.(Leu319Arg)  
14 "BslI,BsrFI,HpaII,MspI,NaeI,NgoMIV"  
15  
16  
17 NM\_001039885.2:c.962C>A NM\_001039885.2 FKRP\_v001 c.962C>A  
18 n.1311C>A c.962C>A p.(Ala321Glu) FKRP\_v001:c.962C>A  
19 FKRP\_v001:p.(Ala321Glu) NM\_001039885.2 NP\_001034974.1  
20 NM\_001039885.2(FKRP\_v001):c.962C>A NM\_001039885.2(FKRP\_i001):p.(Ala321Glu)  
21 "AluI,CviKI\_1" BssHII (2)  
22  
23  
24 NM\_001039885.2:c.983A>C NM\_001039885.2 FKRP\_v001 c.983A>C  
25 n.1332A>C c.983A>C p.(Tyr328Ser) FKRP\_v001:c.983A>C  
26 FKRP\_v001:p.(Tyr328Ser) NM\_001039885.2 NP\_001034974.1  
27 NM\_001039885.2(FKRP\_v001):c.983A>C NM\_001039885.2(FKRP\_i001):p.(Tyr328Ser)  
28 BsrBI  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60